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ABSTRACT
Approximately 1.2 million people in the U.S.A are living with HIV-1. The
development of antiretroviral therapeutics has increased the life expectancy of
people living with HIV-1 (PLWH). Yet, there is a growing concern for aging HIVpositive individuals because about 50% of PLWH develop neurological
impairments, termed HIV-associated neurocognitive disorders (HAND). There
are no treatments for HAND and the mechanisms underlying its pathogenesis
remain unclear. Several factors are implicated in HAND pathogenesis, such as
HIV-1 coat protein gp120, endolysosome and mitochondrial dysfunction, and
elevated levels of reactive oxygen species (ROS). Endolysosomes are acidic
organelles that contain readily releasable stores of cations, such as iron, which
can be released upon de-acidification. Mitochondria are energy producing
organelles, which can also act as cellular sinks for iron when levels of cytosolic
iron are elevated. Iron is an essential metal for human life, but it is tightly
regulated due to its ability to generate ROS through Fenton or Fenton-like
reactions. HIV-1 gp120 increases ROS production, de-acidifies endolysosomes
and reduces mitochondrial respiration. We used U87MG astrocytoma cells,
confocal microscopy, flowcytometry, filter-based imaging, and western blotting to
investigate mechanisms by which HIV-1 gp120 affects endolysosome iron stores,
levels of ROS, and the effects of gp120 on expression levels of iron related

xvii

proteins. In Chapter 2, we describe findings that HIV-1 gp120 de-acidifies
endolysosomes, induced iron release from endolysosomes, increased iron levels
in mitochondria, and that iron from endolysosomes led to increases in levels of
cytosolic and mitochondrial ROS levels. Our findings suggest that endolysosome
iron stores can be upstream of HIV-1 gp120 induced increases in ROS
production. In Chapter 3, we described findings about the responsiveness of our
cells to iron supplementation and chelation, as well as how HIV-1 gp120 affects
expression levels of iron related proteins. We found that 24 h treatment with HIV1 gp120 increased the cell surface expression levels of ferroportin (FPN), an iron
export protein, but we did not observe any changes in other iron related proteins.
Our findings might suggest that U87MG cells increase cell surface FPN in order
to regulate cytosolic iron levels. We considered our findings from Chapter 2 and
3 as evidence that HIV-1 gp120 induces lysosomal stress. In Chapter 4, we
outlined a new concept in understanding how endolysosomes adapt to their
environment during different stress inducing events; this was termed “lysosome
stress response” (LSR). We provided criteria and a working definition for LSR.
We also highlighted how LSR is observed in other organellar stress responses.
Taken together, these findings provide a mechanism by which HIV-1 gp120
affects ROS production. Moreover, this work highlights endolysosomes as a
potential upstream therapeutic target for any disease in which elevated ROS is
implicated and broadens our understanding of cellular biology.

xviii

CHAPTER 1
INTRODUCTION
A Brief History of HIV/AIDS
Globally, human immunodeficiency virus (HIV) has infected over 75 million
people. There are currently 38 million people living with HIV (PLWH). In the USA,
the first reports of acquired immune deficiency (AIDS) were made in 1981
(Gottlieb et al., 1981; Masur et al., 1981). Two years later, HIV was isolated and
identified as the causative agent of AIDS (Barre-Sinoussi et al., 1983; Gallo et
al., 1984). There are two main types of HIV: HIV-1 and HIV-2. HIV-1 is the more
pathogenic strain and is the focus of our work (Deeks, Overbaugh, Phillips, &
Buchbinder, 2015).
HIV-1 Replication Cycle
HIV-1 is a retrovirus that is composed of two copies of single-stranded RNA
(ssRNA). The viral genes and other integral proteins necessary for viral
replication are enclosed by a capsid composed of the viral protein p24. The
capsid is further enclosed by a viral envelope glycoprotein (gp) complex, gp160,
which is comprised of gp120 and gp41 (German Advisory Committee Blood,
2016). The primary receptor for HIV-1 is CD4, which is expressed on the surface
of T-lymphocytes, monocytes, macrophages and dendritic cells (Deeks et al.,
2015). HIV also uses co-receptors, chemokine receptors CCR5 and CXCR4, to
enter target cells (Connor, Sheridan, Ceradini, Choe, & Landau, 1997). Once the
1

virus has attached to the proper receptors it undergoes fusion and uncoating
events which allows it to release its proteins and ssRNA into the cytoplasm. Then
using its reverse transcriptase enzyme, the ssRNAs are reverse transcribed into
viral DNA, which is then transported into the nucleus and integrated into the host
genome (German Advisory Committee Blood, 2016). After genomic integration of
viral DNA, it is transcribed into viral mRNA by host cell transcription machinery.
Then the newly transcribed viral mRNA is exported into the cytosol where it is
translated into viral proteins, assembled, and packed into a new virion (German
Advisory Committee Blood, 2016). Virions mature and bud from host cell
membranes. Viral proteins are then cleaved by a viral protease finally forming
mature virus.
Clinical Progression of HIV-1 Infection
There are three stages that describe the clinical course of HIV infection;
1) primary infection, 2) clinical latency, and 3) AIDS (Pantaleo & Fauci, 1996).
During primary infection HIV RNA levels are detectable in the blood, which leads
to an adaptive immune response which is partially effective in reducing initial viral
load (Pantaleo & Fauci, 1996). At this point infected persons can enter into a
latency phase that can last from a few months to years even in the absence of
treatment (Deeks et al., 2015; Pantaleo & Fauci, 1996). As time goes on during
the latency period, PLWH progressively lose CD4+ T cells and begin to exhibit
symptoms of chronic inflammation (Deeks et al., 2015). Eventually, the CD4+
T cell count drops to the point where PLWH exhibit AIDS. The brains of AIDS
patients are susceptible to infections such as cryptococcal and tubercular
2

meningitis, toxoplasma encephalitis, and progressive multifocal
leukoencephalopathy (Clifford & Ances, 2013; Deeks et al., 2015). The
development of effective antiretroviral therapeutics (ART) has greatly reduced
the incidence of AIDS and its associated complications.
Development of Antiretroviral Therapy
In the late 1990s and into the 2000s there were great advances in the
development of anti-HIV-1 drugs. ARTs are not a cure for HIV-1; however, it has
been successful in suppressing viral replication (Arts & Hazuda, 2012). Indeed,
ART has made living with HIV-1 a manageable chronic disease (Arts & Hazuda,
2012). These drugs have prolonged the lives of PLWH by decades (Antiretroviral
Therapy Cohort, 2017).
ARTs inhibit various stages of the HIV life cycle (Arts & Hazuda, 2012). There
are 6 classes of ARTs; 1) non-nucleoside reverse transcriptase inhibitors,
2) nucleoside reverse transcriptase inhibitors, 3) integrase inhibitors, 4) protease
inhibitors, 5) entry inhibitors, and 6) co-receptor antagonists (Arts & Hazuda,
2012; Pau & George, 2014). Although these drugs are effective in suppressing
the spread of HIV-1, they are not able to eliminate the virus completely from
already infected cells (Arts & Hazuda, 2012). ART regimens are strict and PLWH
must adhere to them daily for the rest of their lives. If the drugs are not taken
consistently there is a chance for a re-spreading of the virus. Previously, ARTs
were burdensome to PLWH because they had to take multiple pills every day.
Today, the development of combined ART (cART) in a single pill has helped with
the very real issue of adherence to the treatment regimen (Arts & Hazuda, 2012).
3

Despite, their effectiveness, these ARTs are not very effective at crossing the
blood brain barrier (BBB) and this leaves the brain as a potential reservoir site for
the virus. (Scutari, Alteri, Perno, Svicher, & Aquaro, 2017). Despite extensive
efforts to increase the brain penetrance of cART this continues to be a major
limitation of these treatment strategies. (Fiandra, Capetti, Sorrentino, & Corsi,
2017; Letendre et al., 2008).
HIV-1 in the Brain
During early stages of HIV-1 infection, the virus invades the central nervous
system (CNS) and targets microglia and to a lesser extent astrocytes (An,
Groves, Gray, & Scaravilli, 1999; Ellis et al., 1997; Price & Brew, 1988). Because
of the BBB, ARTs have low brain penetrance (Scutari et al., 2017). This issue
has led some researchers to suggest that the brain may behave as a reservoir
for HIV-1 (Gray et al., 2014). Although debated within the field, astrocytes have
been suggested as harbors of HIV-1 (Al-Harthi, Joseph, & Nath, 2018). One
mechanism for HIV-1 uptake into astrocytes is endocytosis (Chauhan, Mehla,
Vijayakumar, & Handy, 2014). Others have shown that lysosomotropic agents
such as chloroquine, which blocks endosome maturation, leads to an increased
detection of HIV-1 DNA and p24 in astrocytes (Vijaykumar, Nath, & Chauhan,
2008). Recently, one group demonstrated in vivo that astrocytes can be infected
with HIV-1 and even infect peripheral tissue through trafficking of infected CD4+
T cells out of the brain, even in the presence of cART (Lutgen et al., 2020).
Neurons cannot be infected by HIV-1 but they are vulnerable to damage caused
by soluble factors such as HIV-1 proteins transactivator of transcription (Tat) and
4

gp120, which are both secreted from infected cells. These HIV-1 proteins are
likely contributors to the pathogenesis of HIV-1 associated neurocognitive
disorders (HAND) (Ru & Tang, 2017; Scutari et al., 2017).
HIV-Associated Neurocognitive Disorder
Approximately, 19 million people worldwide are affected by HAND, which is an
overarching term for neurological impairment in PLWH (Antinori et al., 2007;
Clifford & Ances, 2013). Clinical manifestations of HAND range from
asymptomatic (mild) to dementia (severe) (Clifford & Ances, 2013). HAND is
subclassified into 3 categories, in order of most severe to least severe; HIVassociated dementia (HAD), mild neurocognitive disease (MND), and
asymptomatic neurocognitive impairment (ANI) (Antinori et al., 2007). When
AIDS is left untreated, a subset of patients develop HAD, which is characterized
by dementia resembling that observed in late stage Alzheimer’s and Parkinson’s
disease (Navia, Cho, Petito, & Price, 1986; Navia, Jordan, & Price, 1986; Snider
et al., 1983). Since the advent of cART, HAND severity has shifted toward milder
forms (Dore et al., 1999; Dore et al., 2003; McArthur, Steiner, Sacktor, & Nath,
2010). MND and ANI are categorized based on neuropsychometric testing
abnormalities with or without functional impairment in activities of daily living
(Clifford & Ances, 2013). During the cART era, MND and ANI patients have more
impairments in learning, memory, and executive function; contrasted to HAD
patients which exhibit deficits in attention and concentration, and motor and
behavioral dysfunction (Heaton et al., 2011; Navia, Jordan, et al., 1986; Snider et
al., 1983). There is no treatment for HAND and as PLWH continue to age there is
5

a growing concern to understand the interplay between HIV-1 in the brain of
aging PLWH (High et al., 2012). Therefore, it is important to gain a better
understanding of the underlying mechanisms of HAND pathogenesis with the
hope of discovering effective therapeutic interventions.
As previously mentioned, the prevalence of HAND continues to rise despite
ARTs effectively control of HIV-1 replication (McArthur et al., 2010). Furthermore,
throughout the body (including the brain), ARTs do not completely eliminate
HIV-1 or the production of HIV-1 neurotoxic proteins (T. P. Johnson et al., 2013;
Popovic et al., 2005). Further complicating therapeutics, cARTs are neurotoxic
and induce oxidative stress (Louboutin & Strayer, 2014; Sharma, 2014; Turchan
et al., 2003). HIV-1 proteins such as Tat and gp120, which can be secreted from
infected cells are implicated in the pathogenesis of HAND (Scutari et al., 2017).
HIV-1 Tat induces excitotoxicity, synaptodendritic damage, increase in cytosolic
calcium levels, endoplasmic reticulum (ER) stress, and apoptosis in neurons
(Fan & He, 2016; Haughey, Holden, Nath, & Geiger, 1999; Haughey, Nath,
Mattson, Slevin, & Geiger, 2001; Shin & Thayer, 2013; Zucchini et al., 2013).
Furthermore, Tat induces an upregulation of glial fibrillary acidic protein (GFAP)
which leads to oxidative stress in astrocytes (Fan & He, 2016). Likewise, HIV-1
gp120 induces neuronal damage, neuroinflammation and disrupts autophagy (L.
Chen et al., 2011; El-Hage, Podhaizer, Sturgill, & Hauser, 2011; J. Fields et al.,
2013). Moreover, the interaction between gp120 and its receptor CXCR4 is
suggested to play a role in CNS mediated damage (Scutari et al., 2017; J.
Zhang, Liu, Katafiasz, Fox, & Xiong, 2011). Also included in the contributors of
6

HAND pathogenesis are subcellular organelles including endolysosomes and
mitochondria (J. A. Fields et al., 2016; Gelman et al., 2005).
Endolysosomes
The discovery of the lysosome was a serendipitous affair (de Duve, 2005). This
story began with a Belgian biochemist by the name of Christian de Duve who
was interested in understanding the effects of insulin on the liver. In 1951, the
de Duve laboratory identified glucose-6-phosphatase to be attached to an acidic
precipitable cellular structure. It just so happened that in 1946, a group
developed a centrifugal fractionation method which allowed researchers to
separate four different fractions from cells; 1) nuclear fraction, 2) large granule
fraction which contained mitochondria, 3) a small-granule fraction termed
microsomes, and 4) supernatant (Claude, 1946a, 1946b). This new method
made way for the de Duve laboratory to eventually identify acid phosphatase in a
membrane enclosed sac (de Duve, 2005). By 1955, this group identified other
enzymes within this membrane sac and gave it the name lysosome which is
Greek for “lytic” “body” (de Duve, 2005). Three years later, lysosomes were being
identified in other cell types and was found to be involved in digestion of
endocytosed material (de Duve, 2005). More recently, research has uncovered a
more expansive role of lysosomes in cells. Lysosomes are involved in cation
homeostasis, nutrient sensing, plasma membrane repair, immune response, and
bone resorption through lysosomal exocytosis (Ballabio, 2016; Ballabio &
Bonifacino, 2020; Perera & Zoncu, 2016; Settembre & Ballabio, 2014; H. Xu &
Ren, 2015).
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The greater lysosomal system is comprised of endosomes, multivesicular bodies
(MVB), lysosomes, autophagosomes and autolysosomes (Huotari & Helenius,
2011). Endosomes and lysosomes, referred to as endolysosomes, are single
membrane, acidic vesicles, which contain over 60 hydrolases that function at a
low pH. These organelles range in size from about 0.5-1.5 nm (H. Xu & Ren,
2015). The luminal pH of endolysosomes varies between about 4.5 to 6.0 (H. Xu
& Ren, 2015). Endolysosomes use various membrane-resident channels and
pumps to maintain their acidic luminal environment (Colacurcio & Nixon, 2016;
Steinberg et al., 2010; Trivedi, Bartlett, & Pulinilkunnil, 2020). Endolysosomes
contain various divalent cations such as Fe2+, Zn2+, Ca2+, Mn2+, and Cu2+ (H. Xu
& Ren, 2015). Central to endolysosome function is its ability to maintain its
luminal pH, and insults that lead to an increase in endolysosome pH often result
in organellar and cellular dysfunction. Endolysosome deacidification induces the
release of calcium and iron from these organelles (Christensen, Myers, &
Swanson, 2002; Fernández et al., 2016).
Mitochondria
In 1890, Richard Altman identified a ubiquitous bacterium resembling structure in
cells, which he termed “bioblast.” Carl Benda coined these bioblasts as
mitochondria which is Greek for “thread” “granules” (Ernster & Schatz, 1981;
Pagliarini & Rutter, 2013). Structurally, mitochondria are organized into four main
parts; 1) an outer mitochondrial membrane (OMM), 2) inner mitochondrial
membrane (IMM), 3) intermembrane space (the space between OMM and IMM),
and 4) matrix (space within IMM) (Ernster & Schatz, 1981). Moreover, the IMM
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contain folds termed cristae, which function to increase the surface area of
mitochondria and are sites of oxidative phosphorylation (Ernster & Schatz, 1981).
Mitochondria function to produce energy for various processes throughout cells
(Brand, 2005; Ernster & Schatz, 1981). Indeed, in our parlance mitochondria are
known as the “powerhouse of the cell.”
Within the mitochondrial matrix and on the IMM two biochemical processes occur
which aid the production of energy in the form of adenosine triphosphate (ATP)
(Brand, 2005). The tricyclic acid cycle (TCA), also known as the Krebs cycle,
occurs within the mitochondrial matrix (Alabduladhem & Bordoni, 2021). The
TCA is a series of eight enzymatic steps which consumes and produces citrate,
amongst other molecules. As citrate becomes oxidized and other molecules are
formed two reducing agents are formed, nicotinamide adenine dinucleotide
hydride (NADH) and flavin adenine dinucleotide, hydroquinone form (FADH2)
(Alabduladhem & Bordoni, 2021). These reductants are used as electron donors
to the electron transport chain (ETC). Oxidative phosphorylation is the process
by which ATP is formed (Brand, 2005). The ETC is comprised of four complexes
and an ATP synthase (Brand, 2005). NADH donates electrons to complex I
which drives protons (H+) from the mitochondrial matrix into the IMS. Similarly,
FADH2 donates electrons to complex II, which also leads to H+ translocation to
the IMS. As this process continues there is a buildup of H+ within the IMS
promoting a proton motive force which is an electrochemical gradient of H+ that
drives protons back into the mitochondrial matrix through the ATP synthase
protein (Brand, 2005). As the ATP synthase protein coverts ADP to ATP, oxygen,
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which enters the mitochondrial matrix, is used as a final electron acceptor
forming H2O (Brand, 2005). During oxidative phosphorylation, as electrons are
being transferred to complex I, II, and III, mitochondria can produce ROS, which
can lead to oxidative damage of lipid, DNA, and proteins (Kausar, Wang, & Cui,
2018; Quinlan, Perevoshchikova, Hey-Mogensen, Orr, & Brand, 2013). In
addition, mitochondria play a large role in iron metabolism (D. R. Richardson et
al., 2010). Indeed, the mitochondrial matrix is also the only site for heme
synthesis, which is an important component of hemoglobin, and a major site for
iron sulfur cluster formation (D. R. Richardson et al., 2010).
Iron Metabolism
Systemic Iron Regulation
Iron is an essential element that plays a major role in human physiology such as
oxygen transport, energy production, DNA replication, cell proliferation, and
immunity (Muckenthaler, Rivella, Hentze, & Galy, 2017; Wallace, 2016).
Approximately 2 mg of iron is absorbed daily by enterocytes in the small intestine
(Wallace, 2016). Humans derive iron from their diet. Iron in the diet can be found
in the form of heme or non-heme iron (Wallace, 2016). Heme iron is transported
into enterocytes via a heme transporter, potentially, heme carrier protein 1 or
receptor-mediated endocytosis (Gulec, Anderson, & Collins, 2014). In order for
iron to be taken into enterocytes it must be in its reduced oxidative state, ferrous
iron (Fe2+). Non-heme iron in our diet, e.g. meat and plants, is usually in its
oxidative state, ferric iron (Fe3+) (Gulec et al., 2014). Therefore, enterocytes have
a membrane bound ferric reductase enzyme that is located on the apical brush
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broader membrane that can reduce Fe3+ to Fe2+. Once iron is reduced, it is
transported by divalent metal transporter 1 (DMT1) across the apical brush
broader of enterocytes. Intracellularly, ferrous iron has multiple fates. It can be
taken up into the mitochondrial matrix where it is used to synthesize heme and
iron-sulfur clusters (D. R. Richardson et al., 2010). Because Fe2+ has the ability
to generate free radicals through Fenton chemistry (Figure 1), it is also stored
within an iron storage protein ferritin (FTN) which is found in the cytosol and
mitochondrial matrix. Fe2+ can be transported to FTN via a chaperone protein;
poly-r(C) binding proteins (Shi, Bencze, Stemmler, & Philpott, 2008). Intracellular
Fe2+ has a third fate, it can be exported out from cells and into the circulation. In
order for Fe2+ to enter circulation it needs to pass through the basolateral
membrane of intestinal enterocytes. There is only one known iron exporter,
ferroportin (FPN) which resides on the basolateral membrane of enterocytes or
the surface of other cells (Abboud & Haile, 2000; Donovan et al., 2005; Gulec et
al., 2014). Ferroportin is negatively regulated by hepcidin, which is a hormone
secreted by the liver (Donovan et al., 2005). Fe2+ released from enterocytes
through FPN must be oxidized before it is transported; a copper-containing
ferroxidase enzyme hephaestin is involved in this oxidizing process. When iron is
in its oxidized form it can bind to the iron transport glycoprotein transferrin (TF),
which has a high affinity for two Fe3+ ions. The binding of Fe3+ to transferrin
prevents the formation of Fe3+ hydrolysis which produces insoluble ferric
hydroxides (D. R. Richardson et al., 2010).
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Figure 1.

The Fenton reaction was discovered by H.J.H. Fenton. He
determined that oxidation of ferrous iron or the reduction of ferric
iron in the presence of hydrogen peroxide catalyzes a reaction
that produces hydroxy free radicals. Moreover, a reaction
between two hydrogen peroxide molecules can catalyze the
production of hydroxyl radicals. This image was obtained from
https://www.chemistrylearner.com/fenton-reaction.html
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Cellular Iron Regulation
The diferric-transferrin (Fe2-TF) complex is internalized into cells via receptormediated endocytosis by transferrin receptors (TFR). There are two forms of
transferrin receptors, TFR1 and TFR2. TFR2 is primarily expressed in the liver
and is unresponsive to intracellular iron levels, while TFR1 is ubiquitously
expressed and responsive to intracellular iron levels (Kawabata et al., 2001).
Moreover, TFR1 has a higher affinity for Fe2-TF. In cells, once the Fe2-TF/TFR1
complex is endocytosed into endosomes the iron dissociates from TF due to the
low endolysosome pH (Dunn, Suryo Rahmanto, & Richardson, 2007; Ponka,
1997). The dissociated Fe3+ is then reduced to Fe2+ by the six-transmembrane
epithelial antigen of prostate 3 (STEAP3), an endolysosome resident
ferrireductase. After being reduced, Fe2+ can then be transported into the cytosol
via endolysosome permeable channels such as divalent metal transporter 1
(DMT1) or transient receptor potential mucolipin 1 (TRPML1) (X. P. Dong et al.,
2008; Gruenheid et al., 1999). The Fe2+ released from endolysosomes becomes
part of the liable iron pool (LIP), which is defined as the collection of iron that can
move between proteins and small molecules because it is not bound to proteins
(Ackerman, Lee, & Chang, 2017). In contrast, the static iron pool is understood
as iron bound or incorporated into certain proteins (Ackerman et al., 2017). For
example, in order to prevent Fe2+ from undergoing Fenton chemistry, cells use
the iron storage protein FTN. FTN is a 12- to 24-mer protein that has two
subunits a heavy chain (FTH) and a light chain (FTL). FTH has ferroxidase
activity allowing iron to be stored in its biologically inactive form. Ferritin can bind
up to 4500 iron ions and serves as a major depot for iron (Muckenthaler et al.,
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2017). When LIP levels are low, ferritin can be degraded via lysosomes and the
iron can be released into the cytosol for cellular use (Kurz, Eaton, & Brunk,
2011). As described above, free iron can also be taken up mitochondria, where it
can be incorporated into hemeproteins or iron sulfur clusters. As previously
mentioned, mitochondria contain their own ferritin (Ftmt) (D. R. Richardson et al.,
2010); one study showed that an overexpression of Ftmt decreased cytosolic iron
levels, increased TFR1 levels, and increased mitochondrial iron loading. Thus,
mitochondria act as cellular sinks for iron (Nie, Sheftel, Kim, & Ponka, 2005).
Brain Iron Metabolism
The brain, like other organs, requires iron for metabolic processes. The brain
parenchyma is made up of astrocytes, which are the most abundant brain cell
type and function to maintain brain homeostasis and structural support; neurons,
which send electrochemical messages back and forth; oligodendrocytes, which
myelinate neuronal axons; microglial cells, which provide phagocytosis; and
pericytes, which aid in the formation of brain blood vessels and the maintenance
of the BBB. Iron transport into the brain is largely mediated by the BBB, which
protects the brain from iron overload (Mills, Dong, Wang, & Xu, 2010). Iron
accumulation is observed in aging adults and is one of the known causes of
neurodegenerative diseases (Ashraf, Clark, & So, 2018; Ke & Qian, 2007; Moos,
Rosengren Nielsen, Skjorringe, & Morgan, 2007). Therefore, similar to peripheral
tissues the cells of the CNS have developed extensive regulatory mechanisms to
maintain iron levels.

15

The BBB is comprised of brain vascular endothelial cells (BVECs), which are
joined by tight junctions (Daneman & Prat, 2015). BVECs have a luminal
membrane and an abluminal membrane, which is enclosed by astrocyte end foot
processes (Daneman & Prat, 2015). Ultimately, the BBB forms a physical barrier
to the exchange of material between blood, brain tissue, and fluids (Daneman &
Prat, 2015). TFR1 is localized on the luminal side of BVECs and mediates
transferrin bound iron endocytosis into BVECs (Mills et al., 2010). There is also a
non-transferrin-bound iron (NTBI) entry through vesicular and non-vesicular
import mechanisms, one of which being through serum FTN and potential FTN
receptors on BVECs (Mills et al., 2010) (Figure 2). However, it remains unclear
whether that mode of transport is possible and additional work is required to
characterize different types of NTBI entry into BVECs. In regards to transferrin
bound iron, although still unclear, it has been suggested that channels such as
TRPML1 and DMT1 might release endolysosome iron into the cytosol (Mills et
al., 2010).
The end foot processes of astrocytes surround the BVECs also form connections
with neurons (Daneman & Prat, 2015). Therefore, astrocytes play a pivotal role in
regulating iron influx into the brain parenchyma from brain circulation (Mills et al.,
2010). Uptake of iron into neurons is suggested to be through DMT1 or TFR1
(Ashraf et al., 2018; Dringen, Bishop, Koeppe, Dang, & Robinson, 2007; Qian,
To, Tang, & Feng, 1999). Microglia phagocytose cells and in doing so release
iron from ferritin or iron related proteins (Mills et al., 2010). Oligodendrocytes rely
on T-cell immunoglobulin and mucin domain (Tim-2), a ferritin receptor, to take
16

Figure 2.

Iron transport across the blood brain barrier. A schematic
depicting the transport of iron-bound transferrin across the blood
brain barrier (BBB). On the luminal side of brain vascular
endothelial cells (BVECs), transferrin (TF) bound ferric iron is
taken up into endosomes by transferrin receptor (TF). Once
within endosomes, ferric iron is released from transferrin where it
can then be converted into ferrous iron via endolysosome
resident ferrireductases. Iron can be released from endosomes
into the cytosol via divalent metal transporter 1 (DMT1) or
endosomes containing iron can undergo exocytosis and release
ferric iron into the perivascular space. Iron that is released into
the cytosol is released by iron exporter ferroportin (FPN) located
on the abluminal membrane of BVECs. Once within the brain
parenchyma ferrous iron is converted to ferric iron which can
form complexes with citrate, ATP or ascorbate. Iron can be taken
up by the various cells in the brain parenchyma such as
astrocytes, oligodendrocytes, and neurons. This image is cited
from (Mills et al., 2010).
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up NTBI (Mills et al., 2010). Iron export from brain parenchymal cells is the same
as in peripheral tissues, it is mediated by ferroportin which works in concert with
ceruloplasmin, a cooper-containing ferroxidase enzyme (Mills et al., 2010).
ROS Production and Oxidative Stress
Oxidative stress occurs when there is an imbalance between pro-oxidants and
anti-oxidants within cells. There are nitrogen and oxygen derived pro-oxidants (Di
Meo, Reed, Venditti, & Victor, 2016). In our studies, we focused primarily on
oxygen derived pro-oxidants, which are highly reactive and are generally termed
ROS (Kohen & Nyska, 2002). Superoxide radicals (·O2-), hydrogen peroxide
(H2O2), and hydroxyl radicals (·OH) are commonly defined as ROS.
Intracellularly, there are various locations where ROS is produced. A majority of
ROS is produced in the mitochondria (Diebold & Chandel, 2016). For example,
during oxidative phosphorylation as electrons are being passed along complexes
I, II, and III ·O2- is generated (Nickel, Kohlhaas, & Maack, 2014; Quinlan et al.,
2013). Specifically, complex I and II generate ·O2- in the mitochondrial matrix,
while complex III produces ·O2- in the matrix and IMS (Muller, Liu, & Van
Remmen, 2004; Turrens, 2003). The superoxide produced in the IMS can be
exported into the cytosol through the voltage-dependent anion channels
(VDACs), which are located on the OMM. Within the mitochondrial matrix there is
a superoxide dismutase 2 (SOD2) that quickly converts ·O2- into H2O2, while
cytosolic SOD1 converts ·O2 released by complex III into H2O2 (Weisiger &
Fridovich, 1973) (Figure 3). In the cytosol, Fe2+ can participate in the Fenton
reaction (Fe2+ + H2O2 Fe3+ + OH- + OH·) and produce hydroxyl radicals (Eaton
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& Qian, 2002). In order for the cells to maintain oxidative balance, the levels of
·O2 must be kept low and H2O2 levels should not accumulate (Diebold & Chandel,
2016). Therefore, cells have developed peroxide scavenging (peroxidase)
systems that reduce H2O2 into H2O (Winterbourn, 2013). The two main peroxide
systems are thioredoxin/peroxiredoxin (TRX/PRX) and glutathione/glutathione
peroxidase (GSH/GPX), both of which use the oxidation of NADPH to NAD+ to
reduce H2O2 into H2O (Bindoli, Fukuto, & Forman, 2008). The physiological
consequences of ROS are many including cell death (L. J. Su et al., 2019; Q. Su
et al., 2018; Viviani, Corsini, Binaglia, Galli, & Marinovich, 2001). Oxidative stress
is implicated in various neurodegenerative diseases (Butler & Bahr, 2006; Kausar
et al., 2018; Louboutin & Strayer, 2014).
HIV-1 and Iron
In the context of HIV/AIDS, iron plays a critical role in HIV infections. Iron can
increase HIV-1 replication (Chang et al., 2015; Traore & Meyer, 2004). An
increase in hepcidin peptide leads to enhanced virus replication while increasing
ferroportin can inhibit virus replication (Kumari et al., 2016; Nekhai, Kumari, &
Dhawan, 2013; M. Xu et al., 2010). PLWH have elevated serum iron levels and
some researchers have suggested using iron chelators as an adjuvant therapy
(Chang et al., 2015; Nekhai et al., 2013). Interestingly, CD4+ T cells infected with
HIV-1 and then treated with radiolabeled iron (59Fe) demonstrate an increase in
59Fe

compared to uninfected cells (Chang et al., 2015).
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Figure 3.

Mitochondrial production of reactive oxygen species. During
oxidative phosphorylation superoxide radicals (·O2) are
produced. As electrons pass through complex I and II superoxide
is generated and remains in the mitochondrial matrix where it is
converted to hydrogen peroxide (H2O2) by super oxide
dismutase 2 (SOD2), while superoxide produced by electron
transfer through complex III is released into the cytosol where it
is converted into hydrogen peroxide by SOD1. Hydrogen
peroxide in the presence of iron (II) or cooper participates in
Fenton reaction and results in the production of hydroxyl radicals
(·OH) which can induce cellular damage. On the other hand,
cells have peroxide systems such as thioredoxin/peroxiredoxin
(TRX/PRX) and glutathione/glutathione peroxidase (GSH/GPX)
system, which utilize the oxidation of NADPH to NAD+ to reduce
H2O2 to H2O. This image is modified from (Diebold & Chandel,
2016).
Copyright clearance was obtained from the publisher, Elsevier,
to reproduce figure.
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Moreover, the same study showed an elevation in TFR1 mRNA expression in
HIV-1 infected cells, indicating a reduction in cytosolic iron levels (Chang et al.,
2015). The authors of the study suggested that once the virus had infected CD4+
T-cells, it was attempting to create a “favorable environment for its own
replication” (Chang et al., 2015). HIV-1 proteins Tat and gp120 can increase
levels of ROS and can alter the morphology and functions of endolysosomes and
mitochondria (Avdoshina et al., 2016; M. Bae et al., 2014; Datta, Miller, Afghah,
Geiger, & Chen, 2019; Dawson, Dawson, Uhl, & Snyder, 1993; El-Amine et al.,
2018; J. A. Fields et al., 2016; Foga, Nath, Hasinoff, & Geiger, 1997; Gelman et
al., 2005; Hui, Chen, Haughey, & Geiger, 2012; Shah, Kumar, Simon, Singh, &
Kumar, 2013). Moreover, oxidative stress is implicated in the pathogenesis of
HAND (Louboutin & Strayer, 2014). Therefore, we set out in these studies to
investigate the effects of HIV-1 gp120 on iron signaling and ROS production
between endolysosomes and mitochondria.
Hypothesis
HIV-1 gp120 increases ROS production, and antioxidants, such as
deferoxamine, blocks gp120’s effect (Foga et al., 1997). Mitochondria are known
to be major producers of ROS (Diebold & Chandel, 2016). However, the
mechanisms underlying gp120-induced increases in ROS production remain
unclear. Therefore, in Chapter 2, we tested the hypothesis that HIV-1 gp120induced de-acidification of endolysosomes leads to an efflux of iron from
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endolysosomes and an accumulation of iron in the cytosol and mitochondria, and
subsequent increases in levels of cytosolic and mitochondrial ROS.
Iron is implicated in HIV-1 replication (Chang et al., 2015; Debebe et al., 2007),
and gp120 promotes the production of ROS. It remains unclear how gp120
affects expression levels of iron related proteins. In Chapter 3, we tested the
hypothesis that HIV-1 gp120 treatment decreases TFR1 and IRP2 and increases
FTH and FPN protein levels.
Organellar stress responses in the endoplasmic reticulum and mitochondria are
well characterized. These stress responses are initiated due to a stressor and
promote the restoration of organellar function. However, lysosome stress and
lysosome stress responses are ill-defined. Therefore, in Chapter 4, we used
evidence for the work of others and us to define, prove the existence of, and
provide criteria for lysosome stress responses.
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CHAPTER 2
HIV-1 GP120 INDUCED ENDOLYSOSOME
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Abstract
The HIV-1 coat protein gp120 continues to be implicated in the pathogenesis of
HIV-1 associated neurocognitive disorder (HAND); a condition known to affect
~50% of people living with HIV-1 (PLWH). Autopsy brain tissues of HAND
individuals display morphological changes to mitochondria and endolysosomes,
and HIV-1 gp120 causes mitochondrial dysfunction including increased levels of
reactive oxygen species (ROS) and de-acidification of endolysosomes. Ferrous
iron is linked directly to ROS production, ferrous iron is contained in and released
from endolysosomes, and PLWH have elevated iron and ROS levels. Based on
those findings, we tested the hypothesis that HIV-1 gp120-induced
endolysosome de-acidification and subsequent iron efflux from endolysosomes is
responsible for increased levels of ROS. In U87MG astrocytoma cells, HIV-1
gp120 de-acidified endolysosomes, reduced endolysosome iron levels, increased
levels of cytosolic and mitochondrial iron, and increased levels of cytosolic and
mitochondrial ROS. These effects were all attenuated significantly by the
endolysosome-specific iron chelator deferoxamine, by inhibitors of
endolysosome-resident two-pore channels and divalent metal transporter-1
(DMT-1), and by inhibitors of mitochondria-resident DMT-1 and mitochondrial
permeability transition pores. These results suggest that oxidative stress
commonly observed with HIV-1 gp120 is downstream of its ability to de-acidify
endolysosomes, to increase the release of iron from endolysosomes, and to
increase the uptake of iron into mitochondria. Thus, endolysosomes might
represent early and upstream targets for therapeutic strategies against HAND.
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Introduction
HIV-1 associated neurocognitive disorders (HAND) affects about 50% of people
living with HIV-1 (PLWH) despite effective viral suppression achieved using
antiretroviral therapies (ART) (McArthur et al., 2010). Clinically, HAND presents
with deficits in cognition, memory, and motor function (Clifford & Ances, 2013);
the severity varies from mild (asymptomatic) to severe (dementia) (Antinori et al.,
2007). Pathologically, post-mortem brain samples exhibit decreased
synaptodendritic arborization (Everall et al., 1999; Masliah et al., 1992; Masliah
et al., 1997), Alzheimer’s disease-like changes (Brew, Pemberton, Blennow,
Wallin, & Hagberg, 2005), and morphological changes in subcellular organelles
including endolysosomes (Gelman et al., 2005), endoplasmic reticulum (Lindl,
Akay, Wang, White, & Jordan-Sciutto, 2007), and mitochondria (Avdoshina et al.,
2016; J. Fields et al., 2013). Implicated in the pathogenesis of HAND are HIV-1
proteins (Kovalevich & Langford, 2012), reactive oxygen species (ROS) (Turchan
et al., 2003) as well as ART drugs used to treat PLWH (Heaton et al., 2011).
However, the full spectrum of underlying mechanisms of HAND remains unclear.
Several soluble factors, including the HIV-1 proteins transactivator of
transcription (Tat) and glycoprotein 120 (gp120) continue to be implicated in the
pathogenesis of HAND (Kovalevich & Langford, 2012). Tat and gp120 are
neurotoxic, decrease synaptodendritic arborization (J. Fields et al., 2013; Fitting
et al., 2013; Toggas, Masliah, & Mucke, 1996), and disrupt intracellular levels of
calcium and iron (Festa, Gutoskey, Graziano, Waterhouse, & Meucci, 2015;
Haughey et al., 2001; Nath, Padua, & Geiger, 1995). Furthermore, Tat and
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gp120 are capable of affecting the structure and function of subcellular
organelles including endolysosomes and mitochondria (M. Bae et al., 2014; Datta
et al., 2019; J. A. Fields et al., 2016; Hui, Chen, Haughey, et al., 2012).
Endosomes and lysosomes, collectively referred to here as endolysosomes, are
dynamic organelles involved in the trafficking and degradation of intracellular
cargo. Endolysosomes are acidic organelles that help regulate a wide variety of
essential physiological functions including plasma membrane repair, cell
homeostasis, energy metabolism, nutrient-dependent signal transduction, and
immune responses (Ballabio & Bonifacino, 2020; Bird, Trapani, & Villadangos,
2009; Jaiswal, Andrews, & Simon, 2002; Mony, Benjamin, & O'Rourke, 2016;
Settembre, Fraldi, Medina, & Ballabio, 2013). Additionally, endolysosomes
contain readily releasable stores of biologically important cations including
calcium and iron (Xiong & Zhu, 2016). De-acidification of endolysosomes, such
as has been shown to occur with Tat and gp120 (M. Bae et al., 2014; Hui, Chen,
Haughey, et al., 2012; Pietrella et al., 1998), releases calcium and iron
(Christensen et al., 2002; Fernández et al., 2016) from endolysosomes and
disrupts endolysosome membrane integrity (Hui et al., 2015). These actions of
Tat and gp120 might affect mitochondrial function because calcium and iron
overload in mitochondria can result in increased levels of ROS and cell death via
apoptosis and ferroptosis (Brookes, Yoon, Robotham, Anders, & Sheu, 2004;
Dixon et al., 2012; H. Huang et al., 2017).
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PLWH often exhibit elevated serum iron levels (Chang et al., 2015), and iron has
been implicated in HIV-1 progression and HAND pathogenesis
(Chang et al., 2015; Nekhai et al., 2013; Patton et al., 2017). Extracellular ferric
iron (Fe3+) binds to the iron transport protein transferrin and is endocytosed into
endosomes where it is reduced to ferrous iron (Fe2+). Endolysosomes play an
essential role in maintaining intracellular levels of iron; these acidic organelles
are known to release iron when they are de-acidified and they contain a variety of
cation channels through which iron can be released into the cytosol (X. P. Dong
et al., 2008; Fernández et al., 2016; Kurz et al., 2011).
Through Fenton reactions (Eaton & Qian, 2002), ferrous iron in endolysosomes,
cytoplasm, and mitochondria can generate ROS and can cause oxidative stress.
Oxidative stress continues to be implicated in the pathogenesis of
neurodegenerative diseases including HAND, and others and we have shown
that Tat and gp120 both increase levels of ROS (Foga et al., 1997; S. H. Kim,
Smith, Tan, Shytle, & Giunta, 2015; Viviani et al., 2001). Furthermore, HIV-1
gp120 can damage subcellular organelles, such as endolysosomes and
mitochondria (Avdoshina et al., 2016; M. Bae et al., 2014; J. A. Fields et al.,
2016; Viviani et al., 2001). However, prior to this study nothing was known about
the extent to which gp120-induced release of iron from endolysosomes led to
increased levels of ROS in the cytosol and in mitochondria. Therefore, we tested
the hypothesis that HIV-1 gp120-induced de-acidification of endolysosomes
leads to an efflux of iron from endolysosomes and an accumulation of iron in the
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cytosol and mitochondria, and subsequent increases in levels of cytosolic and
mitochondrial ROS.
Methods and Materials
Cell Cultures
Astrocytoma (U87MG) cells were cultured in 1x DMEM (Invitrogen) containing
10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen). U87MG cells
were grown in T75 flasks and then sub-cultured in 35 mm2 dishes (Mattek) or
12- and 24-well plates (Corning); cells were maintained in a 5% CO2 incubator at
37oC. Cells were not used past their tenth passage.
Propidium Iodide Cell Death Assay
Cell death was measured by cellular uptake of propidium iodide (PI) staining
(Sigma-Aldrich) (Crowley et al., 2016). U87MG cells were treated with gp120
(4 nM) in the absence or presence of deferoxamine (DFO; 100 µM) for 30 min or
24 h. Cells were washed once with pre-warmed 1x PBS then suspended in a PI
(20 µg/mL) + PBS buffer for 30 min. Cells were analyzed using our Attune NxT
flow cytometer. PI was excited by the blue (488 nm) excitation laser and light
emission was determined using a BL2 (574/26 nm) filter. Mean fluorescent
intensity, standard error of the mean, and the number (n) cells analyzed for PI
were determined using Attune NxT software (ThermoFisher).
Endolysosome pH Measurements
As previously described (Hui, Chen, Haughey, et al., 2012), endolysosome pH
was measured using a ratiometric indicator-dye LysoSensor Yellow/Blue DND160; a dual excitation dye that measures pH independently of intracellular dye
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concentration. U87MG cells were loaded with 5 to 10 µM DND-160 for 5 min at
37°C. Post-incubation, dye-containing media was removed, and fresh media was
added to the cells just prior to imaging. Light emitted at 520 nm in response to
excitation for 2 msec at 340/380 nm was measured every10 seconds using a
filter-based imaging system (Zeiss Axiovert 200M, Germany). Ratios of light
excited (340/380 nm) versus light emitted (520 nm) were converted to pH using a
calibration curve as previously described (Hui et al., 2012). Using the formula pH
= -log[H+] we calculated percent reductions of intraluminal proton concentrations.
Endolysosome Morphology
Morphological features of plasma membranes, nucleus, and endolysosomes
were determined by immunostaining. Lysosomes were stained with an antiLAMP1 antibody and an Alexa 488 anti-rabbit secondary antibody. Plasma
membranes were stained with an anti-beta1 sodium potassium ATPase antibody
and an Alexa 594 anti-mouse antibody. Nuclei were stained with DAPI. Confocal
scanning microscopy (Zeiss LSM800) was used to acquire z-stack images with a
stack interval of 0.4 µm. Images were acquired and then reconstructed using
Imaris (Oxford Instruments) imaging software (version 9.5).
Endolysosome Iron Measurements
FeRhoNox-1 (Goryo Chemical), which stains specifically for Fe2+ (Hirayama,
2018), was added at a final concentration of 30 µM; U87MG cells were seeded at
a density of 8x103 cells on 35 mm2 dishes and incubated at 37oC for 1 h. After
washing cells twice with 1 x PBS, fresh PBS was added, and cells were imaged
at an excitation wavelength of 537 nm and an emission wavelength of 569 nm
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using our confocal scanning microscope (Zeiss, LSM800). Imaging parameters
were kept the same throughout each set of experiments. Z-stack images were
taken at a stack interval of 0.4 µm. Images were reconstructed using Imaris
(Oxford Instruments) imaging software (version 9.5). The data were represented
as mean fluorescence intensity (MFI).
Cytosolic Iron Measurements
Cytosolic iron levels were measured using PhenGreen™ SK diacetate (PGSK); a
quenching probe for cytosolic iron (Petrat, Rauen, & de Groot, 1999). U87MG
cells were seeded at a density of 2 to 3 x 104 cells on 35 mm2 dishes and
incubated with PGSK at a final concentration of 10 µM for 30 min at 37oC. Cells
were washed three-times with 1 x PBS, collected, suspended and analyzed using
our Attune NxT flow cytometer (ThermoFisher). PGSK was excited using the blue
(488 nm) excitation laser and light was captured after passing through the BL1
(530/30 nm) emission filter. Mean fluorescent intensities, standard error of the
mean, and the numbers (n) of cells analyzed for PGSK were determined using
Attune NxT software (ThermoFisher).
Mitochondrial Iron Measurements
Mitochondrial iron levels were measured using rhodamine B-[2,2'-bipyridine-4-yl)aminocarbonyl]benzyl ester (RDA) (Squarix). RDA is an Fe2+-specific quenching
dye that localizes within mitochondria; it excites at 562 nm and emits at 598 nm
(Rauen et al., 2007). U87MG cells were seeded at a density of 2 to 3 x 104 cells
on 35 mm2 dishes and incubated with 200 nM RDA for 10 min at 37°C. Cells
were washed once and resuspended with 1 x PBS. Z-stack images were
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captured using confocal scanning microscopy (Zeiss LSM800); 11 to 23 slices
were used per z-stack image. Imaging parameters were kept the same
throughout each set of experiments. Images were taken before and 30 min after
the addition of HIV-1 gp120. In the deferoxamine (DFO) treatment group, cells
were incubated with DFO for 1 h followed by the removal of DFO-containing
media and the continuation of the above-described protocol. ImageJ software
was used to merge z-stack images, and to measure mean fluorescence intensity
(MFI) before (time zero) and after (time 30’) the addition of HIV-1 gp120 or
vehicle. MFI per cell was determined by dividing MFI values at time zero by MFI
values at time 30’ (ratio 0/30') and values were expressed as a percentage; the
values were normalized to control values obtained with heat-inactivated HIV-1
gp120 (gp120i).
ROS Measurements in Cytosol and Mitochondria
Cytosolic ROS levels were measured using 2,7-dichlorodihydrofluoroscein
diacetate (DCFDA), which when oxidized produces DCF; DCF excites at 495 nm
and emits at 529 nm. Mitochondrial ROS was measured using MitoSox Red
Superoxide Indicator, which excites at 510 nm and emits at 580 nm. U87MG
cells seeded at a density of 2 to 3 x 104 were incubated with 10 µM DCFDA or 5
µM MitoSox for 30 min at 37ºC in serum-free media. Cells were then washed
twice with 1 x PBS prior to being analyzed using our Attune NxT flow cytometer
(ThermoFisher). DCF-stained cells were excited by the blue (488 nm) excitation
laser and light was emitted through the BL1 (530/30 nm) emission filter. MitoSox
Red stained cells were excited by the blue (488 nm) excitation laser and light
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was emitted by the BL2 (574/26 nm) emission filter. Mean fluorescence
intensities, standard error of the mean, and the number (n) of cells analyzed for
DCF and MitoSox Red were determined using Attune NxT software
(ThemoFisher).
Reagents
Reagents were purchased from ThermoFisher Scientific unless noted otherwise;
CISMBI (Sigma-Aldrich), TRO-19622 (TOCRIS) and Ned-19 (TOCRIS). HIV-1
gp120 IIIb was purchased from ABL Inc. and prepared aliquots were stored at 80oC to prevent freeze-thaw problems.
Statistics
All data were expressed as means and standard errors of the mean (SEM). Data
analyses were completed using GraphPad Prism 8 software. Statistically
significant differences between two groups was determined using a Student's t
test. One-way ANOVA with Tukey’s post-hoc tests were used to compare
differences between multiple groups. p<0.05 was designated to be statistically
significant. All experiments were conducted a minimum of 3 independent times.
Results
HIV-1 gp120 and Baf A1 Decreased Endolysosome Numbers and Increased
Endolysosome pH and Volumes
We determined the effect of HIV-1 gp120 (gp120) treatment on
endolysosome pH. U87MG cells treated with 4 nM gp120 resulted in
endolysosome de-acidification (Figure 4A); peak deacidification was observed by
30 min and pH units were significantly (p<0.0001) increased by
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Figure 4.

HIV-1 gp120 and bafilomycin A1 increased endolysosome pH.
(A) Treatment of U87MG cells with 4 nM HIV-1 gp120 (gp120,
closed squares) or 200 nM of the vacuolar ATPase inhibitor
bafilomycin A1 (Baf A1, closed triangles) de-acidified
endolysosomes; de-acidification by gp120 remained elevated for
30 min. The de-acidification effects of Baf A1 normalized about
12 min following its application. For gp120, peak de-acidification
was observed by 30 min whereas for Baf A1 peak deacidification was observed about 12 min following its application.
(B) HIV-1 gp120 significantly (p<0.0001) increased
endolysosome pH units and Baf A1 significantly (p<0.0001)
increased endolysosome pH units. Data were represented as
mean and SEM. N= 90, ****p<0.0001.
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0.13 ± 0.01 pH units from control values of 5.28 ± 0.01 to values of 5.41 ± 0.01
(Figure 4B). Bafilomycin A1 (Baf A1), a vacuolar ATPase inhibitor that deacidifies endolysosomes (Yoshimori, Yamamoto, Moriyama, Futai, & Tashiro,
1991), was used as a positive control and at a concentration of 200 nM it
significantly (p<0.0001) increased endolysosome pH by 0.18 ± 0.01 pH units
from control values of 5.28 ± 0.01 to 5.46 ± 0.01 (Figure 4B). These changes in
pH corresponded to a 32% reduction in intraluminal proton concentration by
Baf A1 and a 25% reduction by gp120. The endolysosome de-acidification by
gp120 was observed after 5 min and remained elevated for 25 min while the
effects of Baf A1 occurred immediately and normalized about 12 min following its
application (Figure 4A).
Endolysosome de-acidification has been shown by others and us to change
endolysosome morphology including numbers, sizes and positioning within cells
(X. P. Dong et al., 2010; Fernández et al., 2016; Hui, Chen, Haughey, et al.,
2012; D. E. Johnson, Ostrowski, Jaumouille, & Grinstein, 2016; Mauthe et al.,
2018). Because gp120 de-acidified endolysosomes, we next determined the
effects of gp120 on endolysosome numbers, sizes and cellular positioning.
Qualitatively, endolysosomes exposed to heat-inactivated gp120 (gp120i)
displayed a perinuclear distribution pattern, but when exposed to gp120
endolysosomes were enlarged and more dispersed towards plasma membranes
(Figure 5A). Quantitatively, gp120 significantly (p<0.0001) decreased the number
of LAMP1-positive vesicles per cell from 371 ± 19 to 256 ± 34
(Figure 2B), but nevertheless increased significantly (p<0.0001) the total
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Figure 5.

HIV-1 gp120 and bafilomycin A1 decreased endolysosome
numbers and increased endolysosome volumes.
(A) Representative Imaris 9.5 software (Oxford Instruments)
reconstructed and confocal laser scanning microscopy (inset)
images of U87MG cells treated for 30 min with 4 nM heatinactivated gp120 (left panel, gp120i) or HIV-1 gp120 (right
panel, gp120). Lysosomes were stained with anti-LAMP1
antibody, plasma membranes were stained with anti-beta1
sodium potassium ATPase antibody (red), and nuclei were
stained with anti-DAPI antibody. Endolysosomes exposed to
gp120i displayed a perinuclear distribution pattern but were
enlarged and more dispersed towards plasma membranes when
exposed to HIV-1 gp120, scale bar= 5 µm. (B) HIV-1 gp120 and
the positive control bafilomycin A1 (Baf A1) both significantly
(p<0.0001) decreased the number of LAMP1-positive vesicles
per cell. (C) HIV-1 gp120 and the positive control Baf A1 both
significantly (p<0.0001) increased the total volume of LAMP1positive endolysosomes per cell. Data were represented as
mean and SEM. N= 900, ****p<0.0001.
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volume (µm3) of LAMP1-positive vesicles by 47% (Figure 5C). Similarly, Baf A1
significantly (p<0.0001) decreased the number of LAMP1-positive vesicles from
371 ± 19 to 264 ± 19 (Figure 5B) and significantly (p<0.0001) increased the total
volume of LAMP1-positive vesicles by 36% (Figure 5C).
HIV-1 gp120-Induced Decreases in Levels of Endolysosome Iron were
Blocked by an Inhibitor of TPC
De-acidification of endolysosomes can induce the release of divalent cations
from endolysosomes (Christensen et al., 2002; Fernández et al., 2016).
Because of this, we determined the extent to which gp120i, gp120 and Baf A1
decreased levels of endolysosome Fe2+ and whether the inhibitor of
endolysosome associated two pore channels (TPC) trans-Ned-19 (Ned-19)
blocked these decreases because they are permeable to divalent cations such
as Fe2+ (Brailoiu et al., 2009; Calcraft et al., 2009; Fernández et al., 2016).
Qualitatively, treatment of U87MG cells for 30 min with 4 nM of gp120 but not
gp120i decreased FeRhoNox-1 fluorescence staining for Fe2+ (Figure 6A).
Quantitatively, gp120 significantly (p<0.01) decreased levels of endolysosome
iron by 41% (Figure 6B); the positive control Baf A1 significantly (p<0.0001)
decreased levels of endolysosome iron by 66% and this decrease was
significantly (p<0.01) greater than that produced by gp120 (Figure 6B). Next, we
investigated the extent to which the release of endolysosome Fe2+ induced by
gp120 involved endolysosome-resident TPCs. As expected, we observed a
robust co-localization between FeRhoNox-1 and LAMP1 staining regardless of
the treatments applied (Figure 6C-F). Qualitatively, HIV-1 gp120 decreased
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Figure 6.

HIV-1 gp120 decreased levels of endolysosome Fe2+ and these
decreases were blocked by an inhibitor of two pore channels.
(A) Representative confocal laser confocal microscopy images of
U87MG cells treated for 30 min with either heat-inactivated
gp120 (left panel, gp120i) or 4 nM HIV-1 gp120 (right panel,
gp120). Treatment of U87MG cells for 30 min with 4 nM gp120
but not gp120i decreased FeRhoNox-1 fluorescence staining for
Fe2+, scale bar= 5 µm (B) Levels of endolysosome Fe2+ as
indicated by mean fluorescence units (MFI) for FeRhoNox-1
staining were significantly decreased by gp120 and by
Baf A1 (p<0.0001); the decrease produced by Baf A1 was
significantly (p<0.01) greater than that produced by HIV-1 gp120.
(C–F) Representative confocal laser scanning microscopy
images of U87MG cells treated for 30 min with (C) gp120i,
(D) 10 µM Ned-19 (E) 4 nM gp120 or (F) 10 µM Ned-19 added
30 min prior to the addition of gp120. Cells were labelled with
FeRhoNox-1 (red) for endolysosome stores of Fe2+ (left panels),
Cell-Light LAMP1-GFP BacMam 2.0 for endolysosomes (middle
panels), and merged FeRhoNox-1 and LAMP1 images (right
panels); scale bar = 5 µm. (G) MFI values for FeRhoNox-1
staining were significantly (p<0.01) decreased by gp120 and
these decreases were significantly (p<0.01) blocked by 10 µM
Ned-19. Data were represented as mean and SEM. N = 900,
**p<0.01, **p<0.0001.
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FeRhoNox-1 staining in endolysosomes and these decreases were blocked by
the Ned-19 (Figure 6 E-F). Compared to control treatments with gp120i, 4 nM
gp120 decreased significantly (p<0.01) levels of endolysosome iron (Figure 6G)
and caused marked changes in endolysosome morphology (Figure 6A); these
effects of gp120 were significantly (p<0.01) blocked by pretreatment of cells with
Ned-19 (Figure 6G).
Deferoxamine, and Inhibitors of Two Pore Channels and Divalent Metal
Transporter 1, Reduced HIV-1 gp120-Induced Increases in Cytosolic Iron
and ROS Levels, and Deferoxamine Reduced Basal Levels of Cytosolic
ROS
Having found that gp120 caused an increased release of Fe2+ from
endolysosomes, we next sought to determine the extent to which and
mechanisms by which gp120 affected levels of cytosolic Fe2+ and levels of
cytosolic reactive oxygen species (ROS). Cytosolic Fe2+ levels were measured
with the quenching metal indicator PhenGreen SK™ (PGSK) (Petrat et al., 1999).
4 nM HIV-1 gp120 significantly (p<0.0001) increased levels of cytosolic Fe2+ by
about 40% (Figure 7A). Pre-treatment with 100 µM deferoxamine (DFO), a
specific chelator of endolysosome Fe2+, significantly (p<0.0001) blocked
gp120-induced increases in cytosolic Fe2+ (Figure 7A). Because levels of ROS
are increased by Fe2+ through Fenton-reaction chemistry, we determined the
extent to which endolysosome iron released by gp120 affected cytosolic ROS
levels. 4 nM gp120-induced a significantly (p<0.0001) increased cytosolic ROS
levels by about 66% (Figure 7B). By itself, 100 µM DFO significantly (p<0.0001)
inhibited cytosolic levels of ROS and DFO significantly (p<0.0001) blocked
gp120-induced increases in cytosolic ROS (Figure 7B).
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Figure 7.

DFO, Ned-19 and CISMBI blocked HIV-1 gp120-induced
increases in levels of cytosolic iron and ROS. (A) Levels of
cytosolic Fe2+ were measured using the “turn-off” quenching dye
PhenGreen SK™ (PGSK). Data were transformed to the
reciprocal of mean fluorescence intensity (1/MFI) to illustrate
more clearly the ability of HIV-1 gp120 (gp120) to increase levels
of cytosolic Fe2+. Levels of cytosolic Fe2+ were significantly
(p<0.0001) increased by 30 min treatment with 4 nM gp120. Pretreatment of cells for 1 h with 100 µM deferoxamine (DFO), an
endolysosome-specific Fe2+ chelator, significantly (p<0.0001)
blocked gp120-induced increases in levels of cytosolic Fe2+.
Levels of cytosolic Fe2+ were not significantly affected by vehicle
control (PBS). (B) Levels of cytosolic ROS using 2,7dichlorodihydrofluoroscein (DCF) were significantly (p<0.0001)
increased by 30 min treatments of 4 nM gp120. Pre-treatment of
cells for 1 h with 100 µM DFO significantly (p<0.0001) decreased
basal levels of cytosolic ROS and significantly (p<0.0001)
blocked gp120-induced increases in cytosolic ROS. (C) Pretreatment of cells with 10 µM Ned-19, an inhibitor of
endolysosome associated two pore channels, significantly
(p<0.05) blocked gp120-induced increases in levels of cytosolic
ROS. (D) Pre-treatment of cells with 100 µM CISMBI, an inhibitor
of divalent metal transporter 1, significantly (p<0.01) blocked
HIV-1 gp120-induced increases in levels of cytosolic ROS.
Levels of DCF fluorescence were measured as mean
fluorescence intensity (MFI). Data were represented as mean
and SEM. N =10,000, *p<0.05; **p<0.01; ****p<0.0001.
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Based on these findings as well as findings described above, we further
investigated the effects of blocking gp120-induced endolysosome iron release
through TPC on cytosolic ROS levels. Pre-treatment of cells for 30 min with
10 µM of Ned-19 significantly (p<0.05) blocked gp120-induced increases in ROS
(Figure 4C). Because Fe2+ in endolysosomes can also be released through
divalent metal transporter 1 (DMT1), we next determined the extent to which the
DMT1 competitive inhibitor 2-(3-carbamimidoylsulfanylmethyl-benzyl)isothiourea (CISMBI) (Montalbetti, Simonin, Dalghi, Kovacs, & Hediger, 2014)
affected gp120-induced increases in cytosolic ROS and found that CISMBI
significantly (p<0.01) blocked gp120-induced increases in ROS (Figure 7D).
Deferoxamine, and Inhibition of Two Pore Channel, Mitochondrial
Permeability Transition Pore Opening, and Divalent Metal Transporter 1
Blocked HIV-1 gp120-Induced Increases in Mitochondrial Iron and ROS
Mitochondria uptake cytosolic Fe2+ and next we determined the extent to which
gp120-induced release of endolysosome Fe2+ resulted in increased levels of Fe2+
in mitochondria using the “turn-off” quenching dye RDA. Qualitatively, increased
levels of mitochondrial Fe2+ were observed in cells treated with gp120, but not
with gp120i, DFO, or DFO added 1 h prior to gp120 (Figure 8A). Quantitatively,
4 nM gp120 significantly (p<0.0001) increased levels of mitochondrial Fe2+
(decreased RDA MFI) by, on average, about 28% (Figure 8B). Pre-treatment of
cells with 100 µM DFO prior to the addition of gp120 significantly (p<0.0001)
blocked gp120-induced increases in mitochondrial Fe2+ (Figure 8B).
Mechanistically, we next determined the extent to which inhibitors of
mitochondrial permeability transition pore (mPTP) opening, DMT1, and
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Figure 8.

Effects of DFO on HIV-1 gp120-induced increases in
mitochondrial Fe2+ levels. (A) Mitochondrial iron levels were
measured using the quenching dye
rhodamine B-[(2,2’-bipyridine-4-yl)-aminocarbonyl]benzyl ester
(RDA) by confocal laser scanning microscopy. Images are
shown of control cells taken prior to (upper panels) or 30 min
following (lower panels) the addition of heat inactivated HIV-1
gp120 (gp120i), 100 µM deferoxamine (DFO), 4 nM HIV-1 gp120
(gp120), or 4 nM gp120 added 1 h after 100 µM DFO
(DFO+gp120). Qualitatively, gp120 decreased the fluorescence
intensity of RDA staining and DFO blocked the gp120-induced
decreases in RDA fluorescence. (B) U87MG cells treated with
4 nM gp120 significantly (p<0.0001) increased levels of
mitochondrial iron while 1 h pre-treatment with 100 µM DFO
significantly (p<0.0001) blocked gp120-induced increases in
mitochondrial Fe2+ levels. Data were represented as mean and
SEM. N ≥ 25, ****p<0.0001.

48

49

endolysosome TPCs could block gp120-induced increases in levels of
mitochondrial Fe2+. Qualitatively, increased levels of mitochondrial iron were
observed in cells treated with gp120; these increases were blocked by the mPTP
inhibitor TRO-19622 (TRO), the DMT-1 inhibitor CISMBI, and the TPC inhibitor
Ned-19 (Figure 9A). Quantitatively, 4 µM gp120 significantly (p<0.0001)
increased levels of mitochondrial iron (Figure 9B) and these increases were
blocked by pre-treating cells for 30 min with 3 µM of TRO (p<0.0001), 100 µM of
CISMBI (p<0.001), or 10 µM of Ned-19 (Figure 9B).
Because levels of ROS are increased by Fe2+ through Fenton-reaction chemistry,
we determined next the extent to which endolysosome iron released by gp120
affected mitochondrial ROS levels. 4 nM gp120 significantly (p<0.0001)
increased, by about 89%, levels of mitochondrial ROS (Figure 10A). 100 µM
DFO alone did not affect levels of mitochondrial ROS, but did significantly
(p<0.001) block gp120-induced increases in mitochondrial ROS (Figure 10A).
Pretreatment of cells for 30 min with 10 µM Ned-19, 3 µM TRO and 100 µM
CISMBI each significantly (p<0.0001) reduced HIV-1 gp120-induced increases in
mitochondrial ROS (Figure 10B-D).
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Figure 9.

Ned-19, TRO, and CISMBI blocked HIV-1 gp120-induced
increases in mitochondrial Fe2+ levels. (A) Mitochondrial iron
levels were measured using the quenching dye RDA by confocal
laser scanning microscopy. Mitochondrial iron levels of control
cells taken prior to (upper panels) or 30 min following (lower
panels) the addition of heat-inactivated HIV-1 gp120 (gp120i),
4 nM HIV-1 gp120 (gp120), for 30 min with either 3 µM TRO-, an
inhibitor of mitochondrial permeability transition pore (mPTP)
opening; 100 µM CISMBI, an inhibitor of divalent metal
transporter 1; or 10 µM Ned-19, an inhibitor of endolysosome
associated two pore channels, prior to addition with 4 nM gp120.
Qualitatively, gp120 decreased the fluorescence intensity of
RDA, while TRO, CISMBI and Ned-19 each blocked gp120induced decrease in RDA fluorescence. (B) Quantitatively, pretreatment of cells with 3 µM TRO (p<0.0001), 100 µM
CISMBI (p<0.001), or 10 µM Ned-19 (p<0.0001) blocked gp120induced increases in mitochondrial Fe2+ levels. Data were
represented as mean and SEM. N ≥ 25, ***p<0.001,
****p<0.0001
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Figure 10.

DFO, CISMBI, and TRO blocked HIV-1 gp120-induced increases
in mitochondrial ROS levels. (A) MitoSox Red was used as a
measure of mitochondrial ROS and superoxide radicals. Mean
fluorescence intensity (MFI) was significantly (p<0.0001)
increased by 30 min treatment of U87MG cells with 4 nM gp120.
Pre-treatment of cells for 1 h with 100 µM DFO significantly
(p<0.0001) reduced gp120-induced increases in
mitochondrial ROS. (B) HIV-1 gp120-induced increases in
mitochondrial ROS were significantly (p<0.0001) inhibited by
pre-treating cells for 30 min with 10 µM Ned-19. (C) HIV1 gp120-induced increases in mitochondrial ROS were
significantly (p<0.0001) inhibited by pre-treating cells for 30 min
with 3 µM TRO. (D) HIV-1 gp120-induced increases in
mitochondrial ROS were significantly (p<0.0001) inhibited by
pre-treating cells for 30 min with 100 µM CISMBI. Data were
represented as mean and SEM. N ≥ 25, ****p<0.0001.
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Lack of Effect of Vehicle, DFO and HIV-1 gp120 on Cell Viability
The main focus of the studies reported here was to determine the effects of
gp120 on intracellular levels of Fe2+ and links between Fe2+ and ROS; not gp120induced cell death. Accordingly, we determined under our experimental
conditions whether gp120 decreased cell viability (Dawson et al., 1993; Nath et
al., 2000; Yang, Yao, Lu, Wang, & Buch, 2010). Using propidium iodide (PI)
uptake as a measure of cell death (Crowley et al., 2016), no statistically
significant changes in the MFI of PI were observed between control and 4 nM
gp120 treatments for 30 min (Figure 11A) or 24 h (Figure 11B). We also found
that treatments with 100 µM DFO for 30 min (Figure 11A) or 24 h (Figure 11B)
did not affect cell viability in the absence or presence of 4 nM gp120.
Discussion
Over the past three decades, the development and use of effective antiretroviral
therapeutics has transformed HIV-1/AIDS into a chronic therapeutically managed
disease (Arts & Hazuda, 2012). Associated with HIV-1/AIDS in the ART-era is a
high prevalence of a spectrum of cognitive, motor and behavioral symptoms
ranging in intensity from mild (asymptomatic) to severe (dementia) (McArthur et
al., 2010). Collectively, these symptoms are referred to as HIV-1 associated
neurocognitive disorders (HAND) (Antinori et al., 2007; Clifford & Ances, 2013)
and underlying its pathology are findings of increased levels of oxidative stress,
subcellular organelle dysfunction, synaptodendritic damage, and
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Figure 11.

Deferoxamine and HIV-1 gp120 did not affect cell viability.
(A) U87MG cells treated for 30 min with DMSO vehicle (0.1%),
4 nM HIV-1 gp120 (gp120), or 100 µM DFO treatment 1 h prior
to 4 nM gp120 did not significantly affect cell viability as
determined by propidium iodide (PI) uptake. (B) U87MG cells
treated for 24 h with DMSO vehicle (0.1%), 4 nM HIV-1 gp120, in
the absence or presence of 100 µM DFO did not significantly
affect cell viability as determined by PI uptake. PI fluorescence
was measured as mean fluorescence intensity (MFI). Data were
represented as mean and SEM. N=10,000.
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neuroinflammation (Avdoshina et al., 2016; Everall et al., 1999; J. A. Fields et al.,
2016; Gelman et al., 2005; Kovalevich & Langford, 2012; Sanchez & Kaul, 2017;
Saylor et al., 2016; Scutari et al., 2017). Implicated in the pathogenesis of HAND
are soluble factors including the HIV-1 proteins Tat and gp120 as well as ART
treatments themselves (Sanchez & Kaul, 2017; Scutari et al., 2017). Accordingly,
additional investigative work is required to understand better the mechanisms
underlying HAND pathogenesis with the goal of identifying effective therapeutic
interventions.
Here, we showed that HIV-1 gp120 de-acidified endolysosomes, increased the
release of ferrous iron out of endolysosomes, and that this released iron
accumulated in the cytosol and mitochondria where it increased levels of ROS.
Furthermore, we showed the involvement of two pore channels, divalent metal
transporter 1, and mitochondrial permeability transport pore opening in these
effects. By inhibiting iron release from endolysosomes and/or iron uptake into
mitochondria it was possible to block HIV-1 gp120-induced effects on iron
homeostasis and ROS production. Together these results suggest that HIV-1
gp120-induced changes to mitochondria might be downstream of endolysosome
effects and that therapeutic strategies against HAND might be directed against
these upstream targets (Figure 12).
Previously, we reported that HIV-1 gp120 de-acidified neuronal endolysosomes
and that this de-acidification was reversed by the TRPML1 agonist ML-SA1 (M.
Bae et al., 2014). Others too have reported, this time using human monocytes,
that HIV-1 gp120 impaired endolysosome acidification (Pietrella et al., 1998).
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Figure 12.

HIV-1 gp120-induced release of Fe2+ from endolysosomes
results in increased levels of Fe2+ and ROS in cytosol and
mitochondria. HIV-1 gp120 increases endolysosome pH, which
then induces an efflux of ferrous iron (Fe2+) through
endolysosome-resident cation channels including divalent metal
transporter (DMT1) and two pore channels (TPC). Ferrous iron
released from endolysosomes can accumulate in the cytosol and
can be taken into mitochondria via DMT1 or mitochondrial
permeability transition pore (mPTP) opening. Fe2+ can catalyze
Fenton reactions and the generation of reactive oxygen species
(ROS). Mitochondrial ROS may signal back to endolysosomes to
further exacerbate endolysosome dysfunction and the release of
Fe2+. HIV-1 gp120-mediated increases in cytosolic and
mitochondrial ROS can be attenuated with inhibitors of DMT1
(CISMBI), TPC (Ned-19), and mPTP (TRO) channels.
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Here, we confirmed and extended these studies by showing in U87MG
astrocytoma cells that HIV-1 gp120 de-acidified endolysosome pH to an extent
similar to the vacuolar ATPase inhibitor Baf A1; a known endolysosome deacidifier (Yoshimori et al., 1991). Linked to endolysosome de-acidification are
changes to endolysosome morphology including increased endolysosome
volumes, decreased numbers of endolysosomes, and re-positioning of
endolysosomes in cells (Datta et al., 2019; Fernández et al., 2016; Myers,
Prendergast, Holman, Kuntz, & LaRusso, 1991; Ohkuma & Poole, 1981).
Accordingly, we determined the effects of HIV-1 gp120 on endolysosome
volumes and numbers and found that HIV-1 gp120, similar to Baf A1, increased
endolysosome volumes and decreased endolysosome numbers.
Endolysosome positioning inside of cells is influenced by multiple factors
including nutrient status, motor proteins, as well as cytosolic and intra-lysosomal
pH (Heuser, 1989; D. E. Johnson et al., 2016; Korolchuk et al., 2011; Parton et
al., 1991; Pu, Guardia, Keren-Kaplan, & Bonifacino, 2016). Previously, we
reported that HIV-1 gp120 promoted the movement of endolysosomes away from
the nucleus and towards plasma membranes as well as increased endolysosome
exocytosis (Datta et al., 2019) and here using U87MG cells we found similarly
that HIV-1 gp120 and the positive control Baf A1 both caused movement of
endolysosomes towards the periphery of cells and away from their normal more
perinuclear localization. Our results that de-acidified endolysosomes localize
towards the periphery of the cell while more acidic endolysosomes are positioned

61

in a more juxtanuclear manner support findings from multiple laboratories
(Heuser, 1989; D. E. Johnson et al., 2016; Parton et al., 1991).
Endolysosomes contain multiple mechanisms capable of regulating H+ levels as
well as levels of various divalent cations including calcium, iron, copper and zinc
(Abouhamed et al., 2006; X. P. Dong et al., 2008; Fernández et al., 2016).
Endolysosome de-acidification is known to induce the release of these cations
through various channels and transporters (Christensen et al., 2002; Fernández
et al., 2016). Here we focused largely on two-pore channels (TPC) because of
findings that they are endolysosome-resident and when activated by their
endogenous agonist nicotinic adenine dinucleotide phosphate (NAADP) they
release into the cytosol both calcium (Calcraft et al., 2009) and iron (Fernández
et al., 2016). We found that HIV-1 gp120 significantly decreased levels of Fe2+ in
endolysosomes and that HIV-1 gp120 significantly increased levels of Fe2+ in
cytosol and mitochondria. Those findings suggest that HIV-1 gp120-induced
release of ferrous iron from endolysosome stores was sufficient to increase
levels in the cytosol and in mitochondria. This suggestion was supported further
by findings that pre-treatment with deferoxamine, an endocytosed cellimpermeable iron chelator that specifically chelates iron in endolysosomes
(Cable & Lloyd, 1999; Lloyd, Cable, & Rice-Evans, 1991), blocked the HIV-1
gp120-induced increases in the cytosol and mitochondria. Further, inhibiting
mPTP opening and DMT-1 both blocked HIV-1 gp120-induced increases in
mitochondrial iron. Because DMT-1 are localized on mitochondria and
endolysosome membranes (Abouhamed et al., 2006; Wolff, Garrick, Zhao,
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Garrick, & Thevenod, 2014; Wolff et al., 2018), our results with the DMT-1
inhibitor, CISMBI might have been the result of inhibiting endolysosome iron
release and/or blocking mitochondrial iron uptake.
Although, our results suggest that HIV-1 gp120 disrupts endolysosomemitochondrial iron signaling, it is not yet clear how iron is transferred between the
two organelles. One possibility is a "kiss-and-run" mechanism where
endolysosomes dock with and transfer iron to mitochondria (Das, Nag, Mason, &
Barroso, 2016; Hamdi et al., 2016). Alternatively, endolysosome de-acidification
might increase the iron translocation between endolysosomes and mitochondria
and thereby contribute to oxidative stress (Uchiyama et al., 2008).
Regardless, HIV-1 gp120-induced endolysosome iron efflux appears to be an
upstream regulator of cytosolic and mitochondrial iron homeostasis.
A well-known biological consequence of elevated cytosolic and mitochondrial iron
is the production of ROS through Fenton-based chemical reactions. We used
assays to determine effects of HIV-1 gp120 on levels of intracellular hydroxyl
radicals (∙OH), hydrogen peroxide (H2O2), and superoxide radicals (∙O2-) as well
as mitochondrial ∙O2- (Dikalov & Harrison, 2014). Our findings of HIV-1 gp120induced increases in mitochondrial-generated superoxide and cytosolic ROS are
consistent with previous findings that gp120 increased levels of intracellular ROS
(Datta et al., 2019; Lopez et al., 2017; Russo et al., 2005; Shah et al., 2013). Our
findings that pre-treatment with DFO reduced significantly HIV-1 gp120-induced
increases in ROS strongly suggest the involvement of endolysosome iron in
these effects. However, we cannot rule out the possibility that other cations might
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also be involved as well as the possible involvement of endolysosomeindependent mechanisms. Although another study showed that endolysosome
de-acidification led to increased ROS in mitochondria independent of
endolysosome iron release (Yambire et al., 2019), it is possible that their
experimental paradigm of persistent de-acidification resulted in endolysosome
iron depletion as well as sequestration of cytosolic iron by iron storage proteins.
Elevated levels of oxidative stress can result in many biological events up to and
including cell death. Under the conditions used here, we did not find any
significant increase in levels of cell death with 30 min or 24 h treatments with
HIV-1 gp120. However, others have noted ≤10% cell death in U87MG and
SHSY5Y cells treated for 24 h with HIV-1 gp120 (Lopez et al., 2017; Russo et al.,
2005). In contrast, 7–10-day HIV-1 gp120 treatments of U87MG cells increased
cell viability and cell proliferation (Valentín-Guillama et al., 2018). Furthermore,
HIV-1 gp120-induced increases in ROS promoted U87MG cell proliferation
through the activation of glycolysis and the induction of protectant GRP78 (Lopez
et al., 2017; Valentín-Guillama et al., 2018). Cancer cells have elevated ROS and
antioxidant levels compared to non-cancer cells (Liou & Storz, 2010; Schieber &
Chandel, 2014) and further studies are warranted in other types of cells to
determine mechanisms underlying HIV-1 gp120-induced effects on cell
proliferation, antioxidant levels, and cell viability.
Overall, our studies suggest that HIV-1 gp120 can induce a lysosomal stress
response that includes the release of endolysosome stores of ferrous iron.
Further, this release of iron from endolysosomes results in increased levels of
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iron in cytosol and mitochondria that as well as increased oxidative stress. Thus,
crosstalk between endolysosomes and mitochondria might participate in the
pathogenesis of HAND and endolysosome iron might be targeted as an early and
upstream target for therapeutic interventions against HAND.
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CHAPTER 3
EFFECTS OF HIV-1 GP120 ON IRON-RELATED
PROTEINS IN U87MG CELLS
Introduction
Iron is a fundamental element for sustaining life. It is an integral component of
heme and non-heme iron proteins and plays a role in oxygen transport, electron
transfer, DNA synthesis and nitrogen fixation (Anderson, Shen, Eisenstein, &
Leibold, 2012). Iron is primarily found in one of two oxidative states; ferric (Fe3+)
and ferrous (Fe2+). On the one hand, Fe2+ is biologically active and can undergo
Fenton chemistry (Fe (II) + H2O2 Fe (III) + OH- + OH·), which leads to oxidative
stress and even cell death (Eaton & Qian, 2002). On the other hand, Fe3+ is
biologically unavailable. Because of the necessity and toxicity of iron, organisms
have developed systemic and cellular regulatory mechanisms to control the
transport, uptake, storage, and export of iron (Anderson et al., 2012).
Systemically, in humans, Fe3+ is transported through circulation by a plasma
glycoprotein, transferrin (TF) (MacKenzie, Iwasaki, & Tsuji, 2008). Transferrin
receptor 1 (TFR1) is a transmembrane homodimer protein expressed on the
surface of cells and is involved in receptor-mediated endocytosis of iron bound
TF (Ponka & Lok, 1999). Two molecules of Fe3+ bind to one molecule of TF. The
diferric-transferrin complex binds to TFR1 and is endocytosed. Once the
diferric- TF-TFR1 complex is within endosomes, the iron is released from TF
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due to the acidic luminal environment of endolysosomes; TF remains bound to
TFR1 (Ponka & Lok, 1999). Then, TF-TFR1 is recycled back to the plasma
membrane and TF is released from its receptor into the extracellular space
(Ponka & Lok, 1999).
Fe3+ within endosomes is reduced to Fe2+ via endosome-resident ferrireductase
six-transmembrane epithelial antigen of prostate 3 (STEAP3). Fe2+ can be
released through various channels and transporters including endosome-resident
divalent metal transporter 1 (DMT-1) or other iron permeable channels such as
transient receptor potential mucolipin 1 (TRPML1) (X. P. Dong et al., 2008;
MacKenzie et al., 2008). The iron released into the cytosol becomes part of the
intracellular liable iron pool (LIP) where it can be stored, incorporated in
metalloproteins and metalloenzymes, or act as a catalyst for the production of
reactive oxygen species (ROS) (Lv & Shang, 2018).
Intracellularly, cells contain different iron-related proteins that help regulate the
LIP including iron sensors, iron regulatory proteins 1 and 2 (IRP1/2), the iron
storage protein ferritin (FTN); and the iron exporter ferroportin (FPN). IRP1 and
IRP2 regulate iron-related proteins at the post-transcriptional level via the iron
responsive element/iron responsive protein (IRE/IRP) system (Anderson et al.,
2012; Wallace, 2016). IRPs are cytosolic proteins that bind to the 5’- or 3’untranslated regions (UTR) of iron uptake (TFR1, DMT-1), storage (FTN), and
export (FPN) mRNAs (Anderson et al., 2012).
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When levels of iron in the cytosol are low, IRPs bind to the 5’-UTR of FTN and
FPN leading to their transcriptional repression, while IRPs bind to the 3’-UTR of
TFR1 and DMT-1 leading to the stabilization of their mRNAs and translation
(Anderson et al., 2012; W. Wang, Di, D'Agostino, Torti, & Torti, 2007).
Conversely, when cytosolic iron levels are high, IRP2 undergoes proteasomal
degradation, while IRP1 binds to iron-sulfur (4Fe-4S) clusters (Anderson et al.,
2012; W. Wang et al., 2007). This leads to the translational activation of iron
storage and export proteins, while the mRNA transcripts of iron uptake proteins
are degraded by RNases (reviewed by (Anderson et al., 2012; Wallander,
Leibold, & Eisenstein, 2006)).
As previously described, ferritin is an iron storage protein (Torti & Torti, 2002).
Ferritin is comprised of two subunits, a light (FTL) and heavy chain (FTH) that
form a 12- or 24-mer hollow sphere which can bind up to 4500 molecules of Fe3+
(Crichton, Wilmet, Legssyer, & Ward, 2002; Torti & Torti, 2002). The heavy chain
subunit of ferritin contains a ferroxidase center which oxidizes Fe2+ to Fe3+ (Lv &
Shang, 2018). Thus, ferritin is used by cells to store excess cytosolic iron in its
biologically inactive state and protect cells from oxidative stress (Torti & Torti,
2002). When cells are in demand of Fe2+, ferritin is mobilized into lysosomes
where it is degraded and releases Fe3+ into the lysosomal lumen, which can then
be released as Fe2+ from lysosomes (Konijn et al., 1999).
Ferroportin is an exporter of iron that enables iron release from cells into
circulation (MacKenzie et al., 2008). Fe3+ is released by FPN and conversion to
Fe2+ is catalyzed by plasma membrane resident ceruloplasmin, a cooper68

containing ferroxidase (MacKenzie et al., 2008; Wallace, 2016). Ferroportin is
post-translationally regulated by hepcidin, a hormone released by the liver, which
induces the internalization and lysosomal degradation of ferroportin (MacKenzie
et al., 2008).
Experimentally, deferoxamine (DFO) and ferric ammonium citrate (FAC) are
used to modulate iron related protein levels in vitro and in vivo (Hoepken, Korten,
Robinson, & Dringen, 2004; L. B. Li et al., 2019; Varghese, James, Vaulont,
McKie, & Jacob, 2018). DFO is used to reduce cytosolic iron levels, while FAC is
used to increase cytosolic iron levels. DFO is a cell impermeable iron chelator,
which localizes in endolysosomes (Cable & Lloyd, 1999; Lloyd et al., 1991). FAC
is an extracellular iron supplement and is dissolvable as iron salt ferric citrate (H.
Wang et al., 2018). The mechanisms of FAC internalization are not fully
elucidated however FAC appears to enter cells via a TF-TFR1 independent
pathway (L. B. Li et al., 2019; D. R. Richardson & Ponka, 1995; Trinder, Batey,
Morgan, & Baker, 1990).
Of interest, PLWH have elevated levels of serum iron and saturated TF (Chang
et al., 2015). Furthermore, HIV-1 reduces intracellular iron levels, which is
indicated by an increase in TFR1 mRNA levels in CD4+ cells and an increase in
uptake of radiolabeled iron (Chang et al., 2015). In HAND, increased levels of
iron seem to be associated with declined cognitive status (Kallianpur et al.,
2019). Although the underlying mechanisms of HAND pathogenesis are unclear,
oxidative stress and HIV-1 proteins appear to play a role (Kovalevich & Langford,
2012). Others and we have shown that HIV-1 gp120 can promote ROS
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production (Datta et al., 2019; Lopez et al., 2017; Russo et al., 2005; Shah et al.,
2013). HIV-1 gp120 also leads to low levels of cell death (Lopez et al., 2017;
Russo et al., 2005; Valentín-Guillama et al., 2018). HIV-1 gp120 transgenic mice
do not survive as long as wild-type mice and have a high incidence of glioma
tumors (Valentín-Guillama et al., 2018).
Cancer cells have elevated levels of ROS and antioxidants compared to noncancer (Liou & Storz, 2010; Schieber & Chandel, 2014). Because HIV-1 gp120
does not produce cell death in cancer cells (Lopez et al., 2017; Valentín-Guillama
et al., 2018) but does increase levels of ROS, we investigated the effects of HIV1 gp120 on iron related proteins in U87MG cells. It is plausible that U87MG cells
may upregulate iron-related proteins to prevent cell death. The role of HIV-1
gp120 on expression levels of iron related protein levels has yet to be explored.
Therefore, in this study we determined the effects of long-term HIV-1 gp120
treatment on iron-related proteins. Specifically, we hypothesized that 24 h HIV-1
gp120 treatment would decrease TFR1 and IRP2 and increase FTH and FPN
protein levels in U87MG cells.
Materials and Methods
Cell Culture
Astrocytoma (U87MG) cells were cultured in 1x DMEM (Invitrogen) containing
10% fetal bovine serum (R&D systems) and 1% penicillin/streptomycin
(Invitrogen). U87MG cells were grown in T75 and T125 flasks (Invitrogen) and
then sub-cultured in 35 mm2 dishes (MatTek), 6-, 12-, 24-well plates (Corning), or
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100 mm dishes (Corning); cells were maintained in a 5% CO2 incubator (NuAire)
at 37°C. Cells were not used past their tenth passage.
Cell Surface Immunofluorescence Staining
Cells were seeded at 5 x 105 cells in 6 well plates and allowed to attach
overnight. The next day, cells were treated with gp120, DFO, gp120i, or FAC for
24 h. After treatment, cells were harvested in PBS and centrifuged at 1500 x g for
2 min. Post-centrifugation, cells were fixed with 4% PFA for 5 min. Then, cells
were washed twice with 1x PBS and blocked with 0.01% FBS in PBS for 1 h on
ice. Cells were centrifuged at 1500 x g for 2 min and blocking buffer was
removed and cell pellets were washed twice with PBS. After the washing step,
cells were incubated with Alexa Fluor (AF) 647 anti-transferrin receptor antibody
(Abcam, ab187777), AF647 anti-ferroportin antibody (R&D systems; FAB9924R),
or AF647 anti-IgG1 isotype control antibody (Abcam, ab239459). Then, cells
were centrifuged as described above, and washed twice with PBS, and finally
resuspended in PBS. AF647-labeled cells were excited by red (637 nm)
excitation laser and light emission was determined using RL1 (670/14 nm) filter.
Mean fluorescence intensity (MFI), standard error of the mean (SEM), and
n were determined using Attune NxT software (ThermoFisher).
Western Blot
U87MG cells were seeded at a density of 1.5 x 105 cells in 100 mm2 dishes. After
incubation with control or treatments, cells were harvested and lysed in triple
detergent lysis buffer (10 mM NaCl, 50 mM Tris, 0.5% sodium deoxychloate,
10 mM sodium pyrophosphate, 0.1% SDS, 5 mM EDTA, 1 mM DTT) plus
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phosphatase and protease inhibitor cocktail (PIC; ThermoFisher, 78443) and
were mixed three times with 10 min rest between each mixing. Then, cell lysates
were centrifuged at 14,000 x g for 10 min at 4 °C, supernatants were collected,
and protein concentrations were determined by Bradford protein assay (BioRad). Samples were prepared using 4x Laemmli buffer (Bio-Rad). Proteins (515 µg) were loaded into and separated by SDS-PAGE (4-20% precast gels, BioRad) and transferred unto PVDF membranes via iBlot2 Dry Blotting
System (ThermoFisher; IB21001). Total protein staining (LI-COR, 926-1101) was
used to normalize protein samples. Then, membranes were stained with antiferritin antibody (Cell Signaling Technology, #3998S) or anti-transferrin receptor
antibody (Cell Signaling Technology, #13113S). After primary antibody
incubation, membranes were incubated with IRDye goat anti-rabbit secondary
antibody (Licor, 925-32211). Then, blots were imaged using the Odyssey Fc
Imaging System (LI-COR). Image Studio software (LI-COR) was used to quantify
results; quantification of results was performed by densitometry and the results
were analyzed as total integrated densitometric volume values (au). Treatment
groups were normalized to control groups.
Data Analysis
All data were expressed as mean and SEM. Data analyses were completed
using GraphPad Prism 9 software. Statistically significant differences between
two groups was determined using a Student’s t-test. One-way ANOVA with
Tukey’s post-hoc tests and two-way ANOVA with Tukey’s post-hoc tests were
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used to compare differences between multiple groups with one or two factors,
respectively.
Chemicals
Deferoxamine (DFO) and ferric ammonium citrate (FAC) were purchased from
Millipore Sigma (St. Louis, MO, USA). DMSO, PBS, and DMEM were purchased
from ThermoFisher Scientific (Waltham, MA, USA). HIV-1 gp120 was purchased
from ABL Inc. (Rockville, MD, USA). All of the drugs were prepared and stored
as aliquots at -20°C, and HIV-1 gp120 was aliquoted and stored at -80°C until
used. The stock solutions of all chemicals were diluted in H2O, DMSO, or PBS to
reach the final working concentrations applied to cells. The final concentration of
DMSO soluble chemicals or other vehicles, water or PBS, were kept ≤0.1%.
Results
Effects of Deferoxamine on Transferrin Receptor 1 Protein Levels
We first determined how U87MG cells responded to iron supplementation or iron
chelation. We hypothesized that DFO would increase expression levels of TFR1
protein in a concentration- and time-dependent manner. We treated cells for 6 h,
12 h, or 24 h with H2O vehicle control (Ctrl) or DFO at 30 µM, 100 µM, or
300 µM. Then, whole cell lysates were used to determine changes in TFR1
protein levels by Western blotting. 24 h DFO treatment at 30 µM (p<0.01),
100 µM (p<0.01), and 300 µM (p<0.01) induced a 74%, 59%, and 72% increase,
respectively, in TFR1 levels compared to vehicle control (Figure 13A). 24 h DFO
treatment at 30 µM, 100 µM, and 300 µM significantly (p<0.0001) increased
transferrin receptor protein levels compared to 6 h DFO treatment at 30 µM and
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Figure 13.

24 h DFO treatment at 30 µM, 100 µM, and 300 µM increased
transferrin receptor 1 (TFR1) protein levels. Ordinary two-way
ANOVA analysis determined that both time and DFO
concentrations have effects on expression levels of TFR1
protein. Furthermore, there is a significant interaction between
time and DFO concentrations. (A) U87MG cells were treated for
6 h, 12 h, or 24 h with H2O vehicle control (Ctrl), 30 µM, 100 µM,
or 300 µM deferoxamine (DFO). 24 h DFO treatment at 30 µM
(p<0.001), 100 µM (p<0.01), and 300 µM (p<0.001) significantly
increased protein levels of transferrin receptor 1 (TFR1). (Refer
to Table 1 for statistical comparisons) (B) 100 µM DFO treatment
significantly increased TFR1 levels at 6 h (p<0.01) and 24 h
(p<0.0001) time points but not at 12 h compared to vehicle
control. 12 h DFO treatment significantly reduced transferrin
receptor protein levels compared to 6 h (p<0.05) and
24 h (p<0.001) DFO treatment. Data represented as mean and
SEM. N= three independent experiments run in duplicate,
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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300 µM and 12 h DFO treatment at 30 µM, 100 µM, and 300 µM (Figure 13A;
Table 1 and 2). Next, we compared the time point at which 100 µM DFO
increases transferrin receptor protein (Figure 13B). U87MG cells treated for 6 h
with DFO induced a 38% increase (p<0.001) in TFR1 compared to vehicle
control. 12 h DFO treatment did not significantly affect in TFR1 levels compared
to controls but 12 h DFO treatment induced a 35% decrease (p<0.01) in TFR1
levels compared to 6 h DFO treatment. 24 h DFO treatment led to a 59%
increase (p<0.0001) in TFR1 compared to controls and a 55% increase
(p<0.001) compared to 12 h DFO treatment.
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Table 1. Ordinary two-way ANOVA results for figure 13A, with an alpha level set at 0.05. Sum of
squares (SS), degrees of freedom (DF), mean squares (MS).
Source of
% of total
P value
Significant?
Variation
variation
Interaction
22.41
0.0007
Yes
Time
34.55
<0.0001
Yes
Concentration
16.78
0.0004
Yes
ANOVA table
Interaction
Time
Concentration
Residual

SS
1.231
1.898
0.9220
1.442

DF
6
2
3
36

F (DFn, DFd)
F (6, 36) = 5.122
F (2, 36) = 23.68
F (3, 36) = 7.671

Table 2. Ordinary two-way ANOVA with Tukey’s multiple
comparisons for Figure 13A. Only statistically significant
comparisons are shown.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
Tukey's multiple comparisons test
Summary
6 h Treatment
Ctrl vs. 24 h:30 µM
***
Ctrl vs. 24 h:100 µM
**
Ctrl vs. 24 h:300 µM
***
30 µM vs. 24 h:30 µM
***
30 µM vs. 24 h:100 µM
*
30 µM vs. 24 h:300 µM
**
300 µM vs. 24 h:30 µM
****
300 µM vs. 24 h:100 µM
**
300 µM vs. 24 h:300 µM
****
12 h Treatment
Ctrl vs. 24 h:30 µM
***
Ctrl vs. 24 h:100 µM
**
Ctrl vs. 24 h:300 µM
***
100 µM vs. 24 h:30 µM
***
100 µM vs. 24 h:100 µM
*
100 µM vs. 24 h:300 µM
***
300 µM vs. 24 h:30 µM
**
300 µM vs. 24 h:300 µM
*
24 h Treatment
Ctrl vs. 24 h:30 µM
***
Ctrl vs. 24 h:100 µM
**
Ctrl vs. 24 h:300 µM
***
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P value
P=0.0007
P<0.0001
P=0.0004

DFO Increased, while FAC Decreased Cell Surface Expression Levels of
Transferrin Receptor Protein 1
Next, we determined the effects of 24 h DFO and FAC treatment on cell surface
expression levels of TFR1. U87MG cells were treated for 24 h with H2O vehicle
control (Ctrl), 100 µM DFO, or 100 µM FAC and then cells were stained with
AF647-conjugated anti-transferrin receptor 1 antibody. Mean fluorescence
intensity (MFI) of cell surface TFR1 was measured by flow cytometry. DFO
treatment significantly (p<0.0001) increased the MFI for surface TFR1 from
control values of 14,825 ± 13 to 23,458 ± 70 (Figure 14). FAC treatment
significantly (p<0.0001) decreased surface TFR1 MFI from control levels of
14,825 ± 13 to 12,811 ± 20 (Figure 14).
FAC Decreased Transferrin Receptor Protein 1 Expression Levels
We next measured the effects 24 h 100 µM FAC treatment on total protein levels
of TFR1. U87MG cells were treated for 24 h with H2O vehicle (Ctrl) or 100 µM
FAC and whole cell lysates were used to determine changes in TFR1 protein by
Western blotting. 24 h FAC treatment induced a 63% decrease (p<0.01) in TFR1
expression levels compared to vehicle control (Figure 15).
Effects of Ferric Ammonium Citrate on Ferritin Heavy Chain Protein Levels
We next determined the time- and concentration-dependence of FAC-induced
increases in FTH protein levels. We treated cells for 6 h, 12 h, or 24 h with H2O
vehicle control (Ctrl) or FAC at 30 µM, 100 µM, or 300 µM. Then whole cell
lysates were used to determine changes in FTH protein levels by Western
blotting. 6 h FAC treatment at 30 µM (p<0.05), 100 µM (p<0.01), and 300 µM
(p<0.01) induced a 148%, 140%, and 195% increase in FTH protein,
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Figure 14.

DFO increased and FAC decreased cell surface expression
levels of transferrin receptor 1. U87MG cells were treated for
24 h with H2O vehicle control (Ctrl), 100 µM deferoxamine
(DFO), or 100 µM ferric ammonium citrate (FAC). Levels of cell
surface TFR1 were determined by immunofluorescence staining
of U87MG cells with AF647-conjugated anti-transferrin receptor
antibody and fluorescence was measured by flow cytometry.
DFO significantly (p<0.0001) increased TFR1 MFI compared to
vehicle control, while FAC significantly (p<0.0001) decreased
TFR1 MFI. AF647 fluorescence was measured as mean
fluorescence intensity (MFI). Data represented as mean and
SEM. N=921, ****p<0.0001.
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Figure 15.

FAC decreased whole cell expression levels of transferrin
receptor 1 protein. U87MG cells were treated for 24 h with H2O
vehicle control (Ctrl) or 100 µM ferric ammonium citrate (FAC).
FAC treatment significantly (p<0.01) decreased whole cell levels
of transferrin receptor 1 (TFR1) protein. Data is represented as
mean and SEM. N= three independent experiments run in
duplicate.
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respectively, compared to vehicle control. 12 h FAC treatment at 30 µM (p<0.01),
100 µM (p<0.001), and 300 µM (p<0.0001) induced a 203%, 237%, and 331%
increase in FTH protein, respectively, compared to vehicle control. 24 h FAC
treatment at 30 µM (p<0.0001), 100 µM (p<0.0001), and 300 µM (p<0.0001)
induced a 521%, 763%, and 1040% increase in FTH protein, respectively,
compared to vehicle control. 24 h 30 µM treatment induced a 150% increase
(p<0.0001) in FTH protein compared to 6 h FAC 30 µM treatment and a 105%
increase (p<0.0001) in FTH protein compared to 12 h FAC 30 µM treatment. 24 h
FAC treatment at 100 µM induced a 260% increase (p<0.0001) in FTH protein
compared to 6 h FAC treatment at 100 µM and a 156% increase (p<0.0001)
compared to 12 h FAC 100 µM treatment. 24 h FAC treatment at 300 µM
induced a 285% (p<0.0001) increase in FTH protein compared to 6 h FAC
300 µM treatment and a 164% (p<0.0001) increase compared to 12 h FAC
300 µM treatment (Figure 16A; Table 3 and 4).
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Figure 16.

Ferric ammonium citrate increased ferritin heavy chain protein
levels in a time- and concentration-dependent manner. Ordinary
two-way ANOVA analysis determined that both time and FAC
concentrations have effects on expression levels of FTH protein.
Furthermore, there is a significant interaction between time and
FAC concentrations. (A) U87MG cells were treated for 6 h, 12 h,
and 24 h with H2O vehicle control (Ctrl), and 30 µM, 100 µM, or
300 µM ferric ammonium citrate (FAC). 6 h FAC treatment
significantly increased ferritin heavy chain (FTH) protein levels at
30 µM (p<0.05), 100 µM (p<0.01), and 300 µM (p<0.01).
12 h FAC treatment significantly increased FTH protein levels at
30 µM (p<0.01), 100 µM (p<0.001), 300 µM (p<0.0001).
24 h FAC treatment significantly increased FTH protein levels at
30 µM (p<0.0001), 100 µM (p<0.0001), 300 µM (p<0.0001).
(Refer to Table 2 for statistically significant comparisons).
(B) FTH protein was significantly increased with 100 µM FAC
treatment at 6 h (p<0.01), 12 h (p<0.0001), and 24 h (p<0.0001)
compared to vehicle control. 24 h FAC treatment induced a
significant increase in FTH protein compared to FAC treatment
at 6 h (p<0.0001) and 12 h (p<0.0001). Data represented as
mean and SEM. N= three independent experiments run in
duplicate, **p<0.01, ****p<0.0001.
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Table 3. Ordinary two-way ANOVA results for figure 16A, with an alpha level set at 0.05. Sum of
squares (SS), degrees of freedom (DF), mean squares (MS).
Source of
% of total
P value
P value
Significant?
Variation
variation
summary
Interaction
19.08
<0.0001
****
Yes
Row Factor
41.31
<0.0001
****
Yes
Column Factor
36.87
<0.0001
****
Yes
ANOVA table
Interaction

SS
90.13

DF
6

MS
15.02

Row Factor

195.1

2

97.56

Column Factor

174.1

3

58.05

Residual

12.90

36

0.3585
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F (DFn, DFd)
F (6, 36) =
41.91
F (2, 36) =
272.2
F (3, 36) =
161.9

P value
P<0.0001
P<0.0001
P<0.0001

Table 4. Ordinary two-way ANOVA with Tukey’s multiple comparisons for
Figure 16A. Only statistically significant comparisons are shown. *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001
Tukey's multiple comparisons test
Summary
6 h Treatment
Ctrl vs. 6:30 µM
*
Ctrl vs. 6:300 µM
**
Ctrl vs. 12:30 µM
**
Ctrl vs. 12:100 µM
***
Ctrl vs. 12:300 µM
****
Ctrl vs. 24:30 µM
****
Ctrl vs. 24:100 µM
****
Ctrl vs. 24:300 µM
****
30 µM vs. 12:Ctrl
*
30 µM vs. 12:300 µM
**
30 µM vs. 24:Ctrl
*
30 µM vs. 24:30 µM
****
30 µM vs. 24:100 µM
****
30 µM vs. 24:300 µM
****
100 µM vs. 12:300 µM
**
100 µM vs. 24:30 µM
****
100 µM vs. 24:100 µM
****
100 µM vs. 24:300 µM
****
300 µM vs. 12:Ctrl
**
300 µM vs. 24:Ctrl
**
300 µM vs. 24:30 µM
****
300 µM vs. 24:100 µM
****
300 µM vs. 24:300 µM
****
12 h Treatment
Ctrl vs. 12:30 µM
**
Ctrl vs. 12:100 µM
***
Ctrl vs. 12:300 µM
****
Ctrl vs. 24:30 µM
****
Ctrl vs. 24:100 µM
****
Ctrl vs. 24:300 µM
****
30 µM vs. 24:Ctrl
**
30 µM vs. 24:30 µM
****
30 µM vs. 24:100 µM
****
30 µM vs. 24:300 µM
****
100 µM vs. 24:Ctrl
***
100 µM vs. 24:30 µM
****
100 µM vs. 24:100 µM
****
100 µM vs. 24:300 µM
****
300 µM vs. 24:Ctrl
****
300 µM vs. 24:30 µM
**
300 µM vs. 24:100 µM
****
300 µM vs. 24:300 µM
****
24 h Treatment
Ctrl vs. 24:30 µM
****
Ctrl vs. 24:100 µM
****
Ctrl vs. 24:300 µM
****
30 µM vs. 24:100 µM
****
30 µM vs. 24:300 µM
****
100 µM vs. 24:300 µM
****
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Next, we determined the optimal time point at which 100 µM FAC increased
levels of FTH protein. U87MG cells, were treated for 6, 12, and 24 h with H2O
vehicle control (Ctrl) or 100 µM FAC. 6 h (p<0.01), 12 h (p<0.0001), and 24 h
(p<0.0001) FAC treatment induced significantly increased FTH levels by 140%,
237%, and 763% respectively. Increased levels of FTH with 24 h FAC treatment
were significantly (260%) higher (p<0.0001) than 6 h FAC treatments and
significantly (156%) higher (p<0.0001) than 12 h FAC treatments (Figure 16B).
Deferoxamine Decreased Ferritin Heavy Chain Protein Levels
Next, we determined the effects of DFO on protein levels of FTH. U87MG cells
were treated with H2O vehicle control (Ctrl) or 100 µM DFO. 24 h DFO treatment
significantly decreased (p<0.01) FTH levels compared to vehicle control
(Figure 17).
Ferric Ammonium Citrate Decreased Iron Regulatory Protein 2 Protein
Levels
Here we measured the effect of DFO and FAC on IRP2 protein levels. U87MG
cells were treated for 24 h with H2O vehicle control (Ctrl), 100 µM FAC, or
100 µM DFO. FAC treatment significantly decreased (85%) (p<0.0001) IRP2
protein levels compared to vehicle controls. DFO treatment did not significantly
affect IRP2 protein levels (Figure 18).
HIV-1 gp120 did not Alter Levels of Total and Surface Transferrin Receptor
Protein
Next, we determined concentration-dependent effects of HIV-1 gp120 on total
TFR1 protein levels. U87MG cells were treated for 24 h with heat-inactivated
gp120 (gp120i) or HIV-1 gp120 at concentrations: 0.044, 0.444, 1.33, and 4 nM.
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Figure 17.

24 h DFO treatment decreased ferritin heavy chain protein
levels. U87MG cells were treated for 24 h with H2O vehicle
control (Ctrl) or 100 µM DFO. DFO treatment significantly
(p<0.01) decreased ferritin heavy chain (FTH) levels. Data
represented as mean and SEM. N= three independent
experiments run in duplicate, **p<0.01
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Figure 18.

FAC decreased iron regulatory protein 2 (IRP2) protein levels.
U87MG cells were treated for 24 h with H2O vehicle control
(Ctrl), 100 µM FAC or 100 µM DFO. FAC significantly (p<0.0001)
decreased iron related protein 2 (IRP2) protein levels. Data
represented as mean and SEM. N= three independent
experiments run in duplicate, ****p<0.0001.
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A significant (p<0.05) decrease in FTH protein levels was only observed with
1.33 nM gp120; a 23% decrease (Figure 19). Next, we determined the
concentration at which HIV-1 gp120 affects surface expression levels of TFR1
levels. As described above, U87MG cells were treated for 24 h with gp120i or
gp120 at 0.044, 0.444, 1.33, or 4 nM. Then cells were stained with AF647conjugated anti-transferrin receptor 1 antibody and MFI of AF647-positive cells in
each group was measured by flow cytometry. HIV-1 gp120 did not significantly
change cell surface expression levels of transferrin receptor (Figure 20).
HIV-1 gp120 did not Affect Protein Levels of Ferritin Heavy Chain and Iron
Regulatory Protein 2
We next investigated HIV-1 gp120 concentration-dependent changes in FTH
protein levels. U87MG cells were treated for 24 h with gp120i or with gp120 at
varying concentrations as described above. We did not observe any statistically
significant changes in FTH protein (Figure 21). Likewise, when we measured
levels of IRP2 after 24 h treatment with gp120i or gp120 we did not observe a
change in IRP2 levels compared to controls (Figure 22).
HIV-1 gp120 and FAC Increased Cell Surface Expression Levels of
Ferroportin
Based on our findings that 24 h HIV-1 gp120 treatment did not affect IRP2 or
FTH, we hypothesized that HIV-1 gp120 induces an increase in surface levels of
ferroportin (FPN), a plasma membrane resident iron export channel. U87MG
cells were treated for 24 h with gp120i; FAC, which acted as a positive control (G.
Y. Zhao, Di, Wang, Zhang, & Xu, 2014); or 4 nM HIV-1 gp120. Then cells were
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Figure 19.

HIV-1 gp120 decreased total cellular levels of transferrin
receptor 1 protein. U87MG cells were treated for 24 h with heatinactivated gp120 (gp120i) or HIV-1 gp120 at varying
concentrations: 0.044, 0.444, 1.33, and 4 nM. Transferrin
receptor (TFR1) protein levels were significantly (p<0.05)
reduced with 1.33 nM HIV-1 gp120, while treatments with 0.044,
0.444 and 4 nM did not induce a significant decrease in TFR1
protein. Data represented as mean and SEM. N= four
independent experiments run in duplicate, *p<0.05.
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Figure 20.

HIV-1 gp120 treatment did not significantly affect surface levels
of transferrin receptor 1. U87MG cells were treated for 24 h with
heat-inactivated gp120 (gp120i) or with HIV-1 gp120 at varying
concentrations: 0.044, 0.444, 1.33, or 4 nM HIV-1 gp120. There
was no significant change in surface transferrin receptor 1
(TFR1) expression levels at any concentration tested. Levels of
surface TFR1 were determined by immunofluorescent staining of
U87MG cells with AF647-conjugated anti-transferrin receptor
antibody and AF647 mean fluorescence intensity (MFI) was
measured by flow cytometry. Data represented as mean and
SEM. N=1500.
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Figure 21.

HIV-1 gp120 did not alter total cellular levels of ferritin heavy
chain protein. U87MG cells were treated for 24 h with heatinactivated gp120 (gp120i) or HIV-1 gp120 at varying
concentrations: 0.044, 0.444, 1.33, or 4 nM. HIV-1 gp120 did not
induce a significant increase in ferritin heavy chain (FTH) protein
at any concentration. Data represented as mean and SEM. N=
four independent experiments run in duplicate.
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Figure 22.

HIV-1 gp120 did not significantly affect iron regulatory protein
2 protein levels. U87MG cells were treated for 24 h with heatinactivated gp120 (gp120i), 0.044, 0.444, 1.33, or 4 nM HIV1 gp120. There was no significant change in iron regulatory
protein 2 (IRP2) with HIV-1 gp120 treatment. Data represented
as mean and SEM. N=three independent experiments run in
duplicate.

100

101

stained with AF647-conjugated anti-ferroportin antibody and MFI of AF647positive cells were measured by flow cytometry. HIV-1 gp120 significantly
(p<0.0001) increased surface FPN levels with an increase of MFI from control
values of 490 ± 9.4 to 581 ± 9.4. Similarly, FAC treatment significantly (p<0.0001)
increased surface FPN levels with an increase of MFI from control values of
490 ± 9.4 to 554 ± 9.7 (Figure 23).
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Figure 23.

HIV-1 gp120 and FAC increased surface ferroportin levels.
U87MG cells were treated for 24 h with heat-inactivated gp120
(gp120i), 4 nM HIV-1 gp120 (gp120), or 100 µM FAC.
U87MG cell surface levels of ferroportin (FPN) were significantly
increased by gp120 (p<0.0001) and FAC (p<0.0001) treatment.
Levels of surface FPN were determined by immunofluorescent
staining of U87MG cells with AF647-conjugated anti-FPN
antibody and AF647-positive cells mean fluorescence intensity
(MFI) was measured by flow cytometry. Data represented as
mean and SEM. N=2400, ****p<0.0001.
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Discussion
Increases and decreases in levels of the intracellular labile iron pool (LIP) can
affect expression levels of iron related proteins. Because gp120 was found to
release iron from endolysosomes and increase iron levels in the cytosol, we
tested the extent to which deferoxamine (DFO), ferric ammonium citrate (FAC)
and HIV-1 gp120 affect iron-related protein expression levels. In our first set of
experiments we investigated time- and concentration-dependent effects of DFO
on transferrin receptor 1 (TFR1) protein levels in U87MG cells. We hypothesized
that DFO would increase TFR1 protein levels over time in a concentrationdependent manner.
DFO is a hydrophilic cell impermeable iron chelator that localizes in
endolysosomes (Bridges & Cudkowicz, 1984; Cable & Lloyd, 1999; Lloyd et al.,
1991). We treated U87MG cells at 3 different time points with 3 different
concentrations of DFO. U87MG cells were treated for 6 h, 12 h, and 24 h with
30 µM, 100 µM, or 300 µM DFO. We observed a concentration-dependent and
significant increase at 24 h in TFR1 protein levels, the increases we observed at
24 h was consistent with findings reported by others (Bridges & Cudkowicz,
1984; Hoepken et al., 2004).
Next, we determined the time point at which 100 µM DFO treatment increased
TFR1 protein levels. We observed significant increase at 6 h and 24 h but not
12 h. It remains unclear to us as to why there was a reduction in TFR1 protein at
12 h. However, because we did observe a concentration- and time-dependent
increase in TFR1 at 30 µM and 300 µM the results from 12 h incubation with
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100 µM DFO treatment group were likely due to experimental error. DFO can
induce time-dependent increases of surface expression levels of TFR1 protein
(Bridges & Cudkowicz, 1984; Hoepken et al., 2004). Accordingly, we next
determined levels of surface TFR1 after treatment with 100 µM DFO. Surface
expression levels of TFR1 increased by approximately 2-fold in the DFO
treatment group; a finding previously reported (Bridges & Cudkowicz, 1984).
TFR1 protein levels are reciprocally regulated by cytosolic LIP. An increase in
LIP leads to a decrease in TRF1 protein (Hoepken et al., 2004; Ponka & Lok,
1999). Thus, we measured the levels of total and surface TFR1 after 24 h
treatment with 100 µM FAC. As expected, when cells were treated with 100 µM
FAC, total and surface TFR1 expression levels were decreased. These findings
are consistent with findings previously reported by others (Hoepken et al., 2004;
Ponka & Lok, 1999) .
Extracellular iron supplementation with FAC increases the intracellular LIP
(Hoepken et al., 2004; D. Richardson & Baker, 1992; Trinder et al., 1990). An
increase in intracellular iron increases FTH protein (Hoepken et al., 2004; Nash
et al., 2019). Accordingly, we next tested the hypothesis that FAC treatment
would increase FTH protein in a time- and concentration-dependent manner.
Time-dependent increases in FTH expression levels were observed starting at 6
h and these increases were still found with incubations up to 24 h; concentrationdependent increases began at 12 h. There was a robust concentrationdependent increase in FTH protein with 24 h treatments. When we investigated
the time point at which 100 µM FAC increased FTH, we found that beginning at
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6 h FAC increased FTH. Conversely, 24 h treatment with DFO lead to a
reduction in FTH protein levels; these findings were consistent with findings
reported by others (Hoepken et al., 2004).
Iron regulatory protein 2 (IRP2) is a cytosolic RNA-binding protein that acts as a
cytosolic iron sensor (Meyron-Holtz et al., 2004). When cytosolic iron levels are
elevated, IRP2 is degraded via proteasomal degradation (Iwai et al., 1998).
However, when cytosolic iron levels are low IRP2 translocates to the nucleus
where it stabilizes mRNA of iron uptake proteins such as TFR1 (Meyron-Holtz et
al., 2004; Ponka & Lok, 1999). U87MG cells were treated for 24 h with either
100 µM FAC or DFO. As expected, FAC treatment decreased IRP2 levels.
However, 100 µM DFO treatment did not significantly affect IRP2 protein levels.
This finding is inconsistent with the findings of others that DFO significantly
increased IRP2 protein levels in MDA-MB-231 triple-negative breast cancer cells
(C. Chen, Liu, Duan, Cheng, & Xu, 2019). Our findings need to be confirmed
using the cell-permeable iron chelators such as deferiprone or 2’-2’-bipyridine.
Another alternative explanation for the lack of effect of DFO on IRP2 protein
levels could be that a higher concentration or a longer treatment period is
necessary. Nevertheless, these results suggest to us that at 24 h when our
U87MG cells are challenged with either iron supplementation or chelation they
properly response by increasing or decreasing the protein levels of TFR1 and
FTH, while changes in IRP2 protein is only observed in the presence of elevated
cytosolic iron.

107

We next investigated the possible effects of 24 h HIV-1 gp120 treatment on iron
related protein expression levels. We determined concentrations at which HIV-1
gp120 affected total and surface levels of TFR1, and total levels of FTH and
IRP2. Experimentally, effects of HIV-1 gp120 have been observed at
concentrations ranging from picomolar to nanomolar (M. Bae et al., 2014; Datta
et al., 2019; Foga et al., 1997; Vesce, Bezzi, Rossi, Meldolesi, & Volterra, 1997).
Accordingly, we treated U87MG cells with HIV-1 gp120 at varying concentrations
ranging from 0.044 to 4 nM. We did not observe significant changes in surface
TFR1 levels at any concentration of HIV-1 gp120 tested except for a significant
decrease in TFR1 total protein levels at 1.33 nM gp120.
Next, we determine the effects of gp120 on FTH and IRP2 protein expression
levels. We did not observe a change in FTH or IRP2 protein levels at any
concentration of HIV-1 gp120 tested. Others have reported that HIV-1 gp120
increased FTH protein in primary rat cultured neurons (Festa et al., 2015).
Because HIV-1 gp120 might induce iron efflux out of the cell in order to maintain
the intracellular LIP, we next measured expression levels of plasma membrane
resident iron exporter, FPN. Treatment with HIV-1 gp120 resulted in significant
increases in surface expression levels of ferroportin and these results were
comparable to those observed for the positive control FAC. These results
suggested to us that U87MG cells upregulate surface levels of ferroportin and
export iron out of the cells in order to maintain cytosolic iron levels. These
findings might explain the lack of effect of 24 h HIV-1 gp120 treatment on FTN,
IRP2, and TFR1 protein levels.
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This study demonstrates that U87MG cells respond as expected to iron
supplementation and iron chelation. Therefore, the lack of effect that HIV-1
gp120 treatment had on total and surface protein levels of TFR1, and total
protein levels of FTN, and IRP2 was not due to an unresponsive system. What
these findings reveal is that 24 h HIV-1 gp120 treatment of U87MG cells induces
an increase of surface expression levels of FPN which we interpreted as a way
for the cells to maintain LIP. However, in order confirm whether HIV-1 gp120
increases cytosolic iron levels we need to measure those levels. Moreover, other
questions remain one of which being, what are the effects of 24 h HIV-1 gp120
treatment on endolysosome iron stores? Lastly, since cancer cells have elevated
iron levels and ROS levels, and HIV-1 gp120 does not induce cell death in
U87MG but promotes cell proliferation (Liou & Storz, 2010; Lopez et al., 2017;
Schieber & Chandel, 2014; Valentín-Guillama et al., 2018), it is possible that
U87MG cells may be an inadequate cell model to conduct these studies; primary
human astrocytes may be a more appropriate cell model to continue this work.
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Abstract
Extensive work has characterized endoplasmic reticulum (ER) and mitochondrial
stress responses. In contrast, very little has been published about stress
responses in lysosomes; subcellular acidic organelles that are physiologically
important and are of pathological relevance. The greater lysosomal system is
dynamic and is comprised of endosomes, lysosomes, multivesicular bodies,
autophagosomes, and autophagolysosomes. They are important regulators of
cellular physiology, they represent about 5% of the total cellular volume, they are
heterogeneous in their sizes and distribution patterns, they are electron dense,
and their subcellular positioning within cells varies in response to stimuli, insults
and pH. These organelles are also integral to the pathogenesis of lysosomal
storage diseases and it is increasingly recognized that lysosomes play important
roles in the pathogenesis of such diverse conditions as neurodegenerative
disorders and cancer. The purpose of this review is to focus attention on
lysosomal stress responses (LSR), compare LSR with better characterized stress
responses in ER and mitochondria, and form a framework for future
characterizations of LSR. Here, we present the concept of LSR such that the
definition of LSR can be modified as new knowledge is added and specific
therapeutics are developed.
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Introduction
Lysosomes were described in 1955 by Christian de Duve and since that time it
has become increasingly obvious that these acidic organelles are physiologically
important as well as pathologically relevant (de Duve, 2005). Decades ago,
lysosomes were simply thought to be cellular waste bins and endpoints of cellular
degradation events. Now, however, increasingly appreciated are the many
cellular functions homeostatically regulated by lysosomes (Pu et al., 2016;
Settembre et al., 2013; H. Xu & Ren, 2015). They represent about 5% of the total
cellular volume, they are heterogeneous in their sizes and distribution patterns,
they are electron dense, and their subcellular positioning in the cytoplasm varies
in response to stimuli, insults and pH (Holtzman, 1989; Pu et al., 2016; Wartosch,
Bright, & Luzio, 2015).
Lysosomes are integral to the greater lysosomal system, which is also comprised
of endosomes, multivesicular bodies (MVB), autophagosomes, and
autophagolysosomes (Huotari & Helenius, 2011). The importance and the
dynamic nature of endosomes and lysosomes, henceforth referred to as
endolysosomes, continues to be recognized in many ways including the
awarding of Nobel Prizes for the discovery of lysosomes themselves, for
receptor-mediated endocytosis, and for autophagy. These organelles are also
integral to the pathogenesis of lysosomal storage diseases (LSD) and it is
increasingly recognized that lysosomes play important roles in the pathogenesis
of a variety of diseases including neurodegenerative disorders and cancer.
However, when considered in the same vein as other subcellular organelles it
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could be argued that lysosomes do not receive the same degree of recognition
as do other intracellular organelles. While endoplasmic reticulum (ER) and
mitochondria have well known and clearly described stress responses (Huotari &
Helenius, 2011; Martinus et al., 1996; Oakes & Papa, 2015; Valera-Alberni &
Canto, 2018; Q. Zhao et al., 2002), lysosomal stress responses (LSR) are illdefined and have been referred to in the literature only sparingly.
The purpose of this review is to focus attention on LSR and initiate a framework
for its existence, its characterization, its physiological importance, and its
pathological relevance. First, we provide an overview of lysosome biogenesis,
function and dysfunction. Second, we discuss ER and mitochondrial stress
responses in order to provide a context for LSR. Third, we discuss the
characterization of LSR as well as briefly review evidence of LSR in ER and
mitochondrial stress responses. Ultimately, a better understanding of stress
responses in lysosomes may enhance our understanding of cellular physiology
and disease pathogenesis and promote the discovery of new treatments for
diseases.
Overview of Lysosome Biogenesis, Function and Dysfunction
Lysosome Biogenesis
Lysosome biogenesis includes the formation of lysosomes through the
maturation of endocytic vesicles as well as the delivery of newly synthesized
lysosomal enzymes and membrane proteins from the trans-Golgi network
(Kornfeld & Mellman, 1989; Saftig & Klumperman, 2009). The maturation
process of endosomes has been extensively reviewed elsewhere (Huotari &
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Helenius, 2011; Kornfeld & Mellman, 1989; Luzio, Hackmann, Dieckmann, &
Griffiths, 2014; Saftig & Klumperman, 2009), but to provide context we briefly
outline this process here. When extracellular cargo is endocytosed, it is trafficked
into early endosomes and from there it is either recycled back to the plasma
membrane or alternatively it is degraded in lysosomes (Huotari & Helenius, 2011;
Saftig & Klumperman, 2009). Cargo that is destined for degradation stays
contained in endosomes as they mature from early endosomes to late
endosomes, and during this maturation endosomes undergo changes in size and
morphology, become more acidic, traffic perinuclearly, and form intraluminal
vesicles (ILVs); late endosomes containing ILVs are termed MVBs (Huotari &
Helenius, 2011). MVBs can fuse with existing MVBs or late endosomes to form
late endosomes. Late endosomes can fuse with existing lysosomes to form
endolysosomes where degradation of cargo takes place. After fusion,
endolysosomes are converted into lysosomes where acidic hydrolases and
lysosomal membrane proteins are stored (Huotari & Helenius, 2011).
The biosynthesis and delivery of lysosomal enzymes and membrane proteins are
critical for the development and proper functioning of lysosomes. It is well
understood that most newly synthesized lysosomal proteins are posttranslationally modified in the Golgi complex (Braulke & Bonifacino, 2009;
Kornfeld & Mellman, 1989; Luzio et al., 2014; Saftig & Klumperman, 2009).
Lysosomal hydrolases are inserted into the ER lumen where they receive signal
sequence cleavage and core glycosylation followed by trafficking to the cis-Golgi
network (CGN). In the CGN, lysosomal enzymes are unmasked revealing a
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mannose-6-phosphate (M6P) signal (Kornfeld & Mellman, 1989). Once these
proteins reach the trans-Golgi network (TGN), they are recognized by M6P
receptors (M6PR) (Kornfeld & Mellman, 1989; Saftig & Klumperman, 2009). The
binding of M6P tagged proteins to M6PR leads to receptor-dependent vesicle
transport of these proteins to endolysosomes via transport vesicles derived from
the TGN. When lysosomal proteins reach their destination in the acidic
environment of endolysosomes there is a dissociation between M6PRs and M6Ptagged proteins; M6PRs are recycled back to the TGN (Kornfeld & Mellman,
1989; Saftig & Klumperman, 2009).
Lysosome biogenesis (Figure 24) is coordinated by transcription factor EB
(TFEB) (Sardiello et al., 2009). TFEB is a member of the microphthalmiatranscription factor E (MiT/TFE) family of proteins, which are involved in
responding and adapting to intracellular stresses (La Spina et al., 2020; Rehli,
Den Elzen, Cassady, Ostrowski, & Hume, 1999; Steingrimsson, Copeland, &
Jenkins, 2004). The subcellular localization of TFEB is modified by kinases and
phosphatases; phosphorylated TFEB targets the cytosol and de-phosphorylated
TFEB targets the nucleus. The serine/threonine kinase mammalian target of
rapamycin complex 1 (mTORC1) phosphorylates TFEB on serine residues 211
and 122, which results in binding by 14-3-3 proteins. Other serine/threonine
kinases such as mitogen-activated protein kinases 1 (MAPK1), protein kinase B
(Akt), glycogen synthase kinase 3ß (GSK3ß), and mitogen-activated protein
kinase kinase kinase kinase 3 phosphorylate TFEB at Ser142, Ser467,
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Figure 24.

Involvement of mTOR-TFEB in mediating lysosomal stress
responses (LSR). Under unstressed conditions, mammalian
target of rapamycin complex 1 (mTORC1) is localized on
lysosome membranes and phosphorylates transcription factor
EB (TFEB), which is a master regulator of lysosome biogenesis.
Phosphorylated TFEB is bound by 14-3-3 protein promoting the
sequestration of TFEB in the cytoplasm. Under stressful
conditions, which can be caused by any drug, pathogen, or
material that enters the endolysosome system (termed LSR
inducers), lysosomes undergo lysosomal stress responses
(labeled 1-9). We posit that during LSR, stressed lysosomes can
use various signals, one of which being mTOR-TFEB signaling
pathway to promote lysosome biogenesis. When lysosomes are
stressed, mTORC1 is released from lysosome membranes,
calcium is released through calcium permeable channels
(depicted by blue cylinder) into the cytosol where it activates the
cytosolic phosphatase calcineurin. Activated calcineurin
dephosphorylates TFEB allowing it to translocate into the
nucleus where it binds at the coordinated lysosomal expression
and regulation (CLEAR) element of lysosome biogenesis genes.
Subsequently, there is an increase of lysosome-related genes
that lead to the possible restoration of stressed lysosomes. Thus,
LSR may use lysosome biogenesis as one of the pathways to
restore lysosome function.
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Ser134/138, and Ser3, respectively (Hsu et al., 2018; Y. Li, M. Xu, et al., 2016;
Palmieri et al., 2017; Settembre et al., 2011). Phosphorylation of TFEB results in
its cytosolic sequestration and an inhibition of its ability to upregulate lysosome
related genes (Roczniak-Ferguson et al., 2012; Vega-Rubin-de-Celis, PenaLlopis, Konda, & Brugarolas, 2017). Genes that encode for lysosome function
contain a coordinated lysosomal expression and regulation (CLEAR) binding
element in their promoter region. TFEB is dephosphorylated by the
phosphatases calcineurin and protein phosphatase 2 (D. Chen et al., 2018;
Martina & Puertollano, 2018; Medina et al., 2015). Dephosphorylated TFEB
translocates to the nucleus where it binds to CLEAR elements and promotes an
increase of lysosomal-, autophagy-, and mitochondrial-gene expression
(Sardiello et al., 2009; Settembre et al., 2011). Recently, a mechanistic study
revealed how TFEB activity is regulated. STIP1 homology and u-box containing
protein 1 (STUB1) increases TFEB activity by clearing ubiquitinated and
phosphorylated TFEB for proteasomal degradation (Sha, Rao, Settembre,
Ballabio, & Eissa, 2017); mTORC1 phosphorylates TFEB which is proposed to
form heterodimers with non-phosphorylated TFEB thus sequestering TFEB to the
cytosol and preventing the promotion of lysosome biogenesis (Sha et al., 2017).
Lysosome Function
Lysosomes are single membrane acidic organelles that function to degrade
intracellular cargo (Holtzman, 1989). These organelles are heterogeneous in size
(range 0.5 to 1.5 nm), have intraluminal pH values ranging from 4.5 to 6.0, and
contain over 60 different acidic hydrolase enzymes (H. Xu & Ren, 2015). The
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intraluminal pH of lysosomes is maintained by membrane-resident ion channels
and vacuolar-ATPases (Colacurcio & Nixon, 2016; Huotari & Helenius, 2011;
Mindell, 2012; Steinberg et al., 2010).
The acidic lumen of lysosomes provides an environment that is conducive for
optimal activity levels of resident hydrolase enzymes which catalyze the
degradation of cargo that is received via endocytic or autophagic pathways
(Kornfeld & Mellman, 1989). Lysosomes also contain readily releasable stores of
biologically important divalent cations including iron and calcium (Lakpa,
Halcrow, Chen, & Geiger, 2020; H. Xu & Ren, 2015). Intracellularly, the
positioning of endolysosomes is dynamic and their positioning in the cytoplasm
changes markedly according to many factors including cell type and intraluminal
pH; highly acidic endolysosomes are perinuclearly positioned while de-acidified
endolysosomes are re-positioned more towards the periphery of cells near
plasma membranes (D. E. Johnson et al., 2016; Pu et al., 2016).
As mentioned above, lysosomes can receive cargo from endocytic or autophagic
pathways. Once cargo enters the endolysosomal system it has two fates, it can
either be trafficked toward lysosomes to be degraded or it can be recycled to the
plasma membrane. Along the maturation path of endosomes to lysosomes,
intraluminal vesicles begin to form in endosomes thus creating MVBs (van Niel,
D'Angelo, & Raposo, 2018). Cargo within MVBs can be trafficked toward the
plasma membrane to release contents into the extracellular space; these
secreted ILVs are termed exosomes; a type of extracellular vesicles. The release
of exosomes can potentially serve as intercellular signals, therapeutic delivery119

vesicles, and biomarkers for various pathologies (Fais et al., 2016; Lener et al.,
2015; Maia, Caja, Strano Moraes, Couto, & Costa-Silva, 2018; Torrano et al.,
2016).
Autophagy is the means by which cytoplasmic material is degraded. There are
different forms of autophagy such as macro-autophagy (which will be referred to
as autophagy), micro-autophagy (selective autophagy), and chaperone-mediated
autophagy (Galluzzi et al., 2017; Ravikumar et al., 2010). Intracellular cargo is
engulfed by double membrane vesicles called autophagosomes; autophagosome
formation, elongation, and maturation have been reviewed elsewhere
(Ravikumar et al., 2010). Important to the clearance of damaged proteins and
dysfunctional organelles via autophagy is the fusion of autophagosomes with
lysosomes forming autolysosomes (Ravikumar et al., 2010; Galluzzi et al., 2017;
Yim and Mizushima, 2020). In post-mitotic cells, such as neurons, the
autophagic-lysosome system is important for the maintenance of neuronal health
(Kuijpers, Azarnia Tehran, Haucke, & Soykan, 2020).
Apart from their degradative roles, lysosomes also participate in intracellular
nutrient sensing (Perera & Zoncu, 2016; Settembre et al., 2013; H. Xu & Ren,
2015). Lysosomes use mTOR and TFEB to sense and regulate intracellular
nutrient conditions, and the roles of mTOR and TFEB in lysosome nutrient
sensing and cellular function were reviewed extensively elsewhere (Perera &
Zoncu, 2016; Rabanal-Ruiz & Korolchuk, 2018; Settembre et al., 2013). mTOR is
part of a larger protein complex that interacts with lysosome membranes and
senses cytosolic nutrient levels (Rabanal-Ruiz & Korolchuk, 2018). During high
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nutrient conditions, mTOR is recruited to lysosome membranes where it is
activated and initiates downstream effectors that promote cell growth and
proliferation. Conversely, during low nutrient conditions mTOR is inactive,
disassociates from lysosome membranes, and is no longer able to phosphorylate
TFEB; dephosphorylated TFEB promotes the production of lysosome genes
(Napolitano & Ballabio, 2016; Rabanal-Ruiz & Korolchuk, 2018; Sardiello et al.,
2009).
Lysosome Dysfunction
Central to lysosome dysfunction appears to be an increase in intraluminal pH lysosome deacidification. Lysosome de-acidification causes many changes to the
biology of cells including endolysosome positioning in the cytoplasm,
endolysosome sizes and volumes, intraluminal and cytosolic levels of divalent
cations, expression levels and activity levels of acid hydrolases, and the
aggregation of various proteins. And, as we will expand on later, these changes
are also central to the concept of LSR.
The intracellular distribution (positioning) of endolysosomes in the cytoplasm is
affected by endolysosome de-acidification; an increase in endolysosome pH
causes redistribution of lysosomes away from the nucleus and more toward
plasma membranes (Heuser, 1989; D. E. Johnson et al., 2016; Parton et al.,
1991). The cytosolic pH which is influenced by H ions originating from
+

endolysosomes also affects endolysosome positioning (Gottschling & Nystrom,
2017); cytosolic acidification promotes the localization of lysosomes towards
plasma membranes and cytosolic alkalinization leads to perinuclear localization
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of lysosomes (Halcrow et al., 2019; Heuser, 1989; Parton et al., 1991). Although
the biological significance of the pH-dependent re-positioning of endolysosomes
in cells is unclear, some have shown that the location of endolysosomes dictates
their pH and not that their pH dictates the location (D. E. Johnson et al., 2016).
Microtubules and motor proteins also contribute to the translocation and
clustering of endolysosomes (Cabukusta & Neefjes, 2018; Matteoni & Kreis,
1987).
Morphologically, endolysosome de-acidification leads to increased
endolysosome size and an accumulation of undigested intracellular cargo (Myers
et al., 1991; Ohkuma & Poole, 1981; Yoshimori et al., 1991). Endolysosome deacidification also leads to impaired fusion between autophagosomes and
lysosomes, and such changes have been implicated in cell death (Doherty &
Baehrecke, 2018; Mauthe et al., 2018).
Endolysosomes contain readily releasable stores of biologically important
divalent cations including calcium, iron, copper and zinc. De-acidification of
endolysosomes induces the efflux of calcium and iron (Christensen et al., 2002;
Fernández et al., 2016; Hui et al., 2015; Kiselyov et al., 2011; Kurz et al., 2011; J.
H. Lee et al., 2015; H. Xu & Ren, 2015) such that accumulations are measurable
in cytosol, mitochondria, and ER. As a result of decreased levels of cations in
endolysosomes, downstream events can occur including ER stress as well as
mitochondrial redox catastrophe and bioenergetic crisis (Baixauli et al., 2015; Lv
& Shang, 2018; Martina, Diab, Brady, & Puertollano, 2016; Nakashima et al.,
2019; Uchiyama et al., 2008; F. Wang, Gomez-Sintes, & Boya, 2018).
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Lysosome Dysfunction in Neurodegenerative Diseases
Dysfunctional lysosomes have been implicated in several neurodegenerative
disorders including lysosomal storage diseases (LSD), Alzheimer’s disease (AD),
Parkinson's disease (PD), and Huntington's disease (HD) (Audano, Schneider, &
Mitro, 2018; Bonam, Wang, & Muller, 2019; Martini-Stoica, Xu, Ballabio, &
Zheng, 2016; Nguyen, Wong, Ysselstein, Severino, & Krainc, 2019; Wallings,
Humble, Ward, & Wade-Martins, 2019). Neurological complications are observed
in people living with LSD, which are characterized by intra-lysosomal aggregation
of substrates due to mutations in lysosome hydrolases (Platt, 2018). The
inhibition of autophagosome-lysosome fusion and/or the accumulation of
autophagosomes in LSDs could be a potential mechanism underlying the
neuropathogenesis of LSDs (Cao et al., 2006; Fukuda et al., 2006; Koike et al.,
2005; Tanaka et al., 2000). Further observed in LSD are impaired autophagy of
damage mitochondria (mitophagy), increased production of reactive oxygen
species, and bioenergetic crisis.
Amyloid plaques and hyperphosphorylated tau are hallmarks of AD and in AD
there is lysosome dysfunction and an impairment of autophagic flux.
Endolysosomes are the sites where amyloidogenic processing of amyloid
precursor protein occurs; the result is accumulation of amyloid beta (Aß) proteins
Aß40 and Aß42 (Oikawa & Walter, 2019). Neurofibrillary tangles are made from
hyperphosphorylated tau protein and lysosomal enzymes (cathepsin B, D, and E)
generate and digest both Aß and tau (Siman et al., 1993). Lysosome dysfunction
leads to an accumulation of Aß42 in neurons, inhibition of lysosomal cathepsins
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B and E, increases expression of cathepsin D, increases lysosomal pH, impairs
autophagy, and changes permeability of lysosomal membranes (Bi et al., 2000;
Cataldo et al., 1995; Cataldo, Paskevich, Kominami, & Nixon, 1991; Wolfe et al.,
2013). Furthermore, defective autophagy and mitophagy are present in AD
(Reddy & Oliver, 2019).
The hallmark of PD are Lewy bodies which are made up of alpha-synuclein
aggregates in neurons. Genetic mutations in GBA1 (encoding for lysosomal
hydrolase glucocerebrosidase), which is the most common genetic factor of PD
is linked to Lewy body formation (Wallings et al., 2019). Extracellular alphasynuclein can be internalized into endolysosomes via clathrin-mediated
endocytosis leading to changes in lysosome morphology, decreased cathepsin D
activity, increased lysosome pH, and impaired fusion with autophagosomes
(Hoffmann et al., 2019; Winslow et al., 2010).
HD is a rare autosomal-dominant neurodegenerative disease that is caused by a
mutation in the HTT gene leading to HTT mutants (mHTT) prone to aggregation.
mHTT localizes in lysosomes, impairs autophagy, inhibits trafficking of nonmutant HTT to lysosomes, and changes cathepsin activity (del Toro et al., 2009;
Q. Liang, Ouyang, Schneider, & Zhang, 2011; Ratovitski, Chighladze, Waldron,
Hirschhorn, & Ross, 2011; Ravikumar, Duden, & Rubinsztein, 2002; Ravikumar
et al., 2004; Rubinsztein, 2006; Trajkovic, Jeong, & Krainc, 2017; Wallings et al.,
2019). Interestingly, one study shows that mHTT induces perinuclear localization
of lysosomes, reduces lysosome mobility, and promotes premature fusion of
lysosomes with autophagosomes (Erie, Sacino, Houle, Lu, & Wei, 2015).
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Impairment of the autophagic-lysosomal pathway can also promote the release
of toxic intracellular protein aggregates in exosomes; such observations have
been made for AD, PD, and HD (Danzer et al., 2012; Guix, 2020; Miranda et al.,
2018; Perez-Gonzalez, Gauthier, Kumar, & Levy, 2012; Sardar Sinha et al.,
2018; Trajkovic et al., 2017). An increase in the release of undigested substrates
and stored material also occurs in LSDs (Tancini et al., 2019).
ER and Mitochondrial Stress Responses
Stress is a holistic concept that affects organisms at every conceivable level;
minor stressors can promote resilience while major stressors can induce cell
death (Figure 25). Cellular stressors include, but are not limited to, hypoxia, heat
shock, nutrient depletion, and genetic defects (Deus, Yambire, Oliveira, &
Raimundo, 2020). Thus, organelles have developed stress responses to counter
the potential detrimental effects of stress. It happens with ER, it happens with
mitochondria, and, as we will later describe, it happens with lysosomes where
stress responses attempt to maintain and/or restore organellar function. In order
to contextualize the concept of LSR, we will first discuss ER and mitochondria
stress responses.
ER Stress Response
ER helps to maintain calcium homeostasis and lipid metabolism and are sites for
synthesis and proper folding of secretory and transmembrane proteins. Molecular
chaperones in ER bind newly synthesized proteins and facilitate the acquisition
of three-dimensional structures. Proteins are then delivered to Golgi apparatus
where they undergo post-translational modifications. In the case of misfolded
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Figure 25.

Flow diagram depicting responses and outcomes resulting from
lysosomal stress. High levels of lysosomal stress (major) can
lead to transcriptional/translational changes including increases
in lysosome biogenesis. Lower levels of lysosomal stress (minor)
can lead to selective autophagy and/or lysophagy. In either case,
outcomes can include cell life or death.
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proteins, proteins are released from ER into the cytosol where they are targeted
for proteasomal degradation; ER associated degradation (ERAD) (Ruggiano,
Foresti, & Carvalho, 2014). When levels of misfolded proteins exceed ERAD
capacity, ER stress is triggered and accumulation of misfolded and/or unfolded
proteins occurs in the lumen of ER (Bravo et al., 2013; Mori, 2015). In response
to ER stress, the unfolded protein response (UPR) is activated, and this results in
halting the translation of and increasing gene expression of ER folding proteins
(Bravo et al., 2013; Kohno, Normington, Sambrook, Gething, & Mori, 1993; Mori,
2015; Partaledis & Berlin, 1993). UPR was first discovered in 1988 for glucose
deprivation initiating the accumulation of misfolded proteins within the ER lumen,
which then leads to a subsequent transcriptional response to increase ERresident molecular chaperones (Kozutsumi, Segal, Normington, Gething, &
Sambrook, 1988; Mori, 2015).
ER uses three resident transmembrane proteins as sensors of ER stress and
initiators of the UPR signaling pathways; inositol requiring protein 1 alpha (IRE1),
activating transcription factor 6 (ATF6), and protein kinase RNA-like ER kinase
(PERK) (Hetz, 2012; Sasaki & Yoshida, 2015). IRE1 senses ER stress luminally,
is activated via oligomerization and phosphorylation of its cytosolic domain, and
once activated splices immature X box protein 1 (XBP1) mRNA into mature
XBP1 mRNA. After protein translation, XBP1 is translocated into the
nucleuswhere it acts as a transcription factor to promote the expression of ERAD
genes (A. H. Lee, Iwakoshi, & Glimcher, 2003; Yoshida et al., 2003). PERK is an
ER transmembrane protein (Harding, Zhang, Bertolotti, Zeng, & Ron, 2000;
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Harding, Zhang, & Ron, 1999) and similar to IRE1, PERK is activated by
oligomerization and phosphorylation when it senses ER stress luminally
(Harding, Novoa, et al., 2000; Harding, Zhang, et al., 2000). Once activated,
PERK phosphorylates eukaryotic translational initiation factor 2 alpha (eIF2),
which reduces protein translation and increases translation of activating
transcription factor 4 (ATF4); ATF4 is a transcription factor that increases gene
expression of anti-oxidation and pro-apoptotic genes (Harding, Novoa, et al.,
2000; Harding et al., 2003). The ER transmembrane protein ATF6 senses ER
stress and once translocated to Golgi apparatus, it is cleaved by proteases
(Shen, Chen, Hendershot, & Prywes, 2002). Then, the cytosolic domain of ATF6
is translocated to the nucleus to increase the expression of ER chaperone genes
(J. Ye et al., 2000).
Mitochondrial Stress Response
Mitochondria produce energy in the form of adenosine triphosphate (ATP) via
oxidative phosphorylation, serve as sinks for cations such as calcium and iron,
and help maintain redox balance. Although mitochondria contain their own
genome, the majority of mitochondrial proteins are nuclear-encoded and those
proteins are translated in the cytoplasm (Sasaki & Yoshida, 2015). Unfolded
proteins are transported from the cytoplasm into mitochondria via heat shock
protein 70 (HSP70); a molecular chaperone (Ryan & Hoogenraad, 2007). Once
translocated into the inner membrane space of mitochondria, the proper folding
of proteins is assisted by mitochondrial HSP70 (mtHSP70) and mtHSP60 (Endo,
Yamano, & Kawano, 2011; Sasaki & Yoshida, 2015).
129

Mitochondrial stress is characterized by redox catastrophe and bioenergetic
crisis caused by dysfunctional oxidative phosphorylation, increased levels of
ROS, and/or accumulation of misfolded proteins (Hill, Sataranatarajan, & Van
Remmen, 2018). Mitochondrial UPR (UPR ) was first described in 2004 (Yoneda
MT

et al., 2004); it helps restore mitochondrial function (M. L. Huang et al., 2019;
Manoli et al., 2007; Martinus et al., 1996; Q. Zhao et al., 2002) via transcriptional
signaling pathways (Sasaki & Yoshida, 2015) and removing the mitochondrial
genome or mutating matrix proteins (Martinus et al., 1996; Q. Zhao et al., 2002).
Lysosome Stress Response (LSR)
Lysosome Stress
The term “lysosomal stress” appears to have been first mentioned in 1968 in the
context of a freeze-thaw method used to rupture lysosomes (Persellin, 1969).
However, it appeared to take another 50 years before “lysosome stress” was
described as “any disturbance in lysosomal membrane integrity, enzyme
function, or internal pH that leads to cell damage or even diseases" (Lin et al.,
2016). We posit that in addition to membrane integrity, enzyme function and pH,
more recent reports from others and us strongly suggests that additional criteria
be added including size, efflux of cations, organelle repositioning within cells,
protein aggregation, LDL cholesterol accumulation, and increases in reactive
oxygen species (M. Bae et al., 2014; Gowrishankar et al., 2015; He et al., 2018;
Hui, Chen, & Geiger, 2012; Hui, Chen, Haughey, et al., 2012; L. Li et al., 2019;
Lin et al., 2016; Pan, Alamri, & Valapala, 2019; Papadopoulos et al., 2017;
Yogalingam et al., 2017). These criteria are consistent with findings from the
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study of LSDs; mutations in lysosomal acid hydrolases lead to aggregation of
substrates, elevated luminal pH, altered morphology and subcellular distribution
patterns, and lowered luminal concentrations of biologically important metal ions
(Ballabio & Gieselmann, 2009; Fossale et al., 2004; Holopainen, Saarikoski,
Kinnunen, & Jarvela, 2001; S. Lee, Sato, & Nixon, 2011; Lloyd-Evans et al.,
2008; Marques & Saftig, 2019; Platt, 2018; Raben, Roberts, & Plotz, 2007; Sun,
2018; Yanagawa et al., 2007; Zigdon et al., 2017).
Characterization of Lysosome Stress Response (LSR)
In this section we provide a framework for characterizing LSR. The greater
lysosomal system is complex and so too is the nomenclature used to describe
lysosome function, dysfunction and stress. Although there is likely overlap
between the concepts of lysosome stress, LSR and lysosome dysfunction, there
are also differences. Lysosome dysfunction is the progressive accumulation of
undegraded substrates within lysosomes (Settembre & Ballabio, 2014) and we
posit that lysosome stress is a state that lysosomes enter into due to internal or
external stimuli; the lysosome responses to those stimuli characterize LSR.
Currently, we propose nine criteria with which to characterize LSR; (1) increased
intralysosomal pH, (2) increased lysosome size, (3) membrane permeabilization,
(4) cationic efflux, (5) repositioning intracellularly, (6) misfolded protein
aggregation, (7) LDL cholesterol accumulation, (8) redox catastrophe, and (9)
bioenergetic crisis (see Figure 26). Principal among these 9 criteria might be
lysosome de-acidification because lysosome de-acidification can trigger each of
the other 8 criteria involved in LSR. LSR might be distinct from lysosome
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Figure 26.

Lysosome stress response characteristics and examples of
stimuli that cause LSR. Lysosomal stress responses can be
characterized by (1) increased lysosome pH, (2) increased
lysosome size, (3) lysosomal membrane permeabilization,
(4) cationic efflux, (5) intracellular repositioning, (6) intraluminal
protein aggregation, (7) intraluminal accumulation of LDL
cholesterol, (8) redox catastrophe, and (9) bioenergetic crisis.
Endogenous and exogenous stimuli such as the HIV-1 proteins
Tat and gp120, drugs of abuse including methamphetamine and
opioids, nanoparticles, LDL cholesterol, and chloroquine (CQ)
and hydroxychloroquine (HCQ) can induce lysosome stress.
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dysfunction because LSR is the means by which lysosomes attempt to adapt to
environmental cues. The concept of LSR is built on the foundation of lysosome
adaptation, which is the ability of lysosomes to respond to metabolic changes
(Settembre & Ballabio, 2014). Here, we are broadening the idea of lysosome
adaptation; LSR is lysosomal adaptation to stimuli such as pathogens, drugs,
molecules or other material that could affect the greater endolysosome system.
LSR utilizes selective autophagy and transcriptional response machinery in an
attempt to restore lysosome function. Thus, the term – LSR.
For both ER and mitochondrial stress, selective autophagy works to remove
damaged organelles (Chino & Mizushima, 2020; Galluzzi et al., 2017; Kubli &
Gustafsson, 2012; J. R. Liang et al., 2020). When lysosomes are damaged, they
are cleared through selective autophagy; lysophagy (Galluzzi et al., 2017; Yu,
Chen, & Tooze, 2018). Lysophagy detects and clears membrane-permeabilized
endolysosomes (Papadopoulos & Meyer, 2017). Permeabilization of lysosome
membranes leads to the binding of galectins to sugars on the inner leaflet of
lysosome membranes; this initiates ubiquitination and autophagy of damaged
endolysosomes (Koerver et al., 2019; Papadopoulos et al., 2017; Papadopoulos
& Meyer, 2017). Relatedly, the term “endo-lysosomal damage response” was
used to describe autophagic clearance of damaged lysosomes via p97 and other
cofactors (Papadopoulos et al., 2017). Lysophagy may also help with
homeostatically-regulated responses. Although, ER and mitochondrial stress
responses have defined sensors of stress the sensors for LSR are unclear. It is
possible that an increase in lysosome pH can trigger a host of changes,
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described above, that can act as stress signals. For example, lysosome
biogenesis can be promoted by the release of cations from endolysosomes.
Endolysosomes contain levels of calcium approaching those found in ER (Feng
& Yang, 2016) and when de-acidified, readily releasable pools of calcium are
released from endolysosomes and initiate transcriptional responses to increase
lysosome biogenesis via TFEB (Christensen et al., 2002; Hoglinger et al., 2015;
Lu, Sung, Lin, Abraham, & Jessen, 2017; Medina et al., 2015; Settembre et al.,
2013). One potential LSR stress sensor could be the endolysosome resident
transient receptor mucolipin 1 channel (TRPML1). TRPML1 is a divalent cation
efflux channel and is implicated in sensing elevated reactive oxygen species
(X. Zhang et al., 2016). Upon activation, TRPML1 can release calcium, and this
calcium can activate calcineurin and lead to TFEB dephosphorylation (Medina et
al., 2015) (Figure 24).
The status of TFEB during LSR might depend on the magnitude and duration of
the stressor. Under minor stress conditions, which might occur physiologically,
TFEB is phosphorylated by mTORC1 or other kinases, and localized in the
cytosol bound to the phospho-binding 14-3-3 protein (Medina et al., 2015;
Settembre et al., 2013). Under major stress conditions, which might occur
pathologically, TFEB is dephosphorylated and translocates into the nucleus,
activates the CLEAR gene network and leads to an up-regulation of genes
involved in lysosome functioning (Lu et al., 2017; Martini-Stoica et al., 2016).
These responses mirror those of the unfolded protein response (UPR) in the ER,
and those in mitochondria (Bravo et al., 2013; Sasaki & Yoshida, 2015)
135

(Figure 26). Although speculative, such responses may play important roles in
LSR. Therefore, LSR can be posited to be a homeostatic control mechanism that
functions to protect against and/or rescue stressed lysosomes. In the context of
therapeutics, it seems that targeting components of the mTOR-TFEB signaling
pathway restores cellular functions in in vitro and in vivo models of LSD. For
example, TFEB nuclear translocation has been suggested as a potential
therapeutic target against LSDs. In Gaucher disease (GD), the most prevalent
LSD, TFEB overexpression and the restoration of glucocerebrosidase (GCase)
restored lysosome function, at least in GD-derived pluripotent stem cells (Awad
et al., 2015). Similarly, in a drosophila model of GD, mTOR inhibitor rapamycin is
able to partly recover the oxidative stress, locomotor, starvation and stress
phenotypes (Kinghorn et al., 2016). In another study, increased expression levels
of TFEB rescued GCase activity as well as the activity of -hexosaminidase, both
of which are proteins mutated in Tay-Sachs disease (Song et al., 2013).
Moreover, TFEB overexpression in in vitro and in vivo models of Pompe disease
caused a decrease in lysosome size, a reduction of aggregated glycogen, and an
increase in autophagy (Spampanato et al., 2013). Re-acidification of damaged
lysosomes is another potential therapeutic target for LSDs; lysosomal deacidification could be a central mechanism to target in various LSDs and reacidification of lysosomes could be a therapeutic target (Folts, Scott-Hewitt,
Proschel, Mayer-Proschel, & Noble, 2016). Furthermore, re-acidification of
lysosomes was found to have clinical benefits including motor improvement,
weight gain, and prolonged survival (Folts et al., 2016).
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Inducers of LSR
In this section, we have selected to highlight 5 inducers of LSR based on the
literature as well as the work we have completed in our laboratory. We
acknowledge that these are not the only LSR inducers, but they are examples of
how different molecules induce LSR.
Chloroquine and hydroxychloroquine.
Weak-base compounds following protonation accumulate and are trapped in
lysosomes (MacIntyre & Cutler, 1988; Zhitomirsky & Assaraf, 2015); such actions
may initiate LSR. Chloroquine (CQ) and hydroxychloroquine (HCQ) are both
weak base FDA-approved drugs that appear to induce LSR. However, many
other commonly used lysosomotropic agents may also promote LSR (P. M.
Chen, Gombart, & Chen, 2011; Jia et al., 2018; Redmann et al., 2017; Settembre
et al., 2012; Yoshimori et al., 1991; Zhitomirsky et al., 2018). CQ increases
lysosome pH, lysosome size and lysosome membrane permeabilization, as well
as inhibits protein degradation (Khan, Halcrow, et al., 2020; Khan, Lakpa, et al.,
2019; Lu et al., 2017; Wibo & Poole, 1974). CQ impairment of autophagosome
and lysosome fusion results in bioenergetic dysfunction (Redmann et al., 2017).
Further, CQ and HCQ inhibit autophagosome-lysosome fusion and increase
lysosome size (Mauthe et al., 2018). In an in vivo model for age-related macular
degeneration, CQ induced lysosome dysfunction; lysosomes size increased and
lipid accumulation was observed (P. M. Chen et al., 2011). Moreover, CQ and
other lysosomotropic drugs activate TFEB translocation to the nucleus through
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the inhibition of mTOR (Lu et al., 2017; Settembre et al., 2012; Zhitomirsky et al.,
2018).
HIV-1 proteins.
The HIV-1 proteins, transactivator of transcription (Tat) and glycoprotein
120 (gp120) affect endolysosomes and appear to induce LSR. Tat and gp120
de-acidify endolysosomes, alter their positioning intracellularly, increase
lysosome permeabilization, and promote vacuolation (M. Bae et al., 2014; Datta
et al., 2019; Hui, Chen, Haughey, et al., 2012; Pietrella et al., 1998); those effects
help explain findings that Tat and gp120 increase the release of divalent cations
including calcium and iron from endolysosomes (Khan, Chen, & Geiger, 2020;
Khan, Halcrow, et al., 2020; Nath et al., 2000; Nath et al., 1995). In the context of
LSR, the damaging effects of HIV-1 proteins may be due at least in part to
lysosome de-acidification, and the subsequent release of divalent cations from
endolysosomes because acidification of lysosomes via activation of
endolysosome-resident transient receptor mucolipin 1 (TRPML1) channel
protected against gp120-induced changes to lysosomes (M. Bae et al., 2014).
TRPML1 is also a reactive oxygen species (ROS)-sensor and calcium efflux
channel, which promotes TFEB translocation (M. Bae et al., 2014; X. Zhang et
al., 2016). In the context of HIV-1 replication, we studied the escape of HIV-1 Tat
from endolysosomes and showed that HIV-1 Tat increases LTR activation only in
the presence of CQ (Khan, Datta, Geiger, & Chen, 2018). These findings were
interpreted as evidence that CQ-induced de-acidification and lysosome
membrane permeabilization precipitated the escape of HIV-1 Tat from lysosomes
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(Khan et al., 2018; Khan, Halcrow, et al., 2020). The conclusion that lysosome
pH was centrally involved in that response was supported by findings that
lysosome acidification reduced HIV-1 Tat-induced LTR activation (Khan, Lakpa,
et al., 2019).
In addition to HIV-1 proteins, antiretroviral therapeutic (ART) agents used to treat
people living with HIV-1 can also affect endolysosomes. Antiretrovirals are a
class of drugs that inhibit different stages of HIV-1 infection (Pau & George,
2014) and ARTs have been shown to affect endolysosomes (Festa et al., 2019;
Hui et al., 2019). Weak-base ARTs de-acidified endolysosomes and promoted
amyloidogenesis (Hui et al., 2019). These effects might contribute to the
pathogenesis of HIV-1 associated neurocognitive disorder and Alzheimer’s
disease-like pathology in people living with HIV-1 (Afghah, Chen, & Geiger, 2020;
Festa et al., 2019; Hui et al., 2019; Khan, Haughey, Nath, & Geiger, 2019).
Low density lipoprotein (LDL) cholesterol.
Cells internalize exogenous cholesterol through receptor-mediated-endocytosis
and this cholesterol traffics through the endolysosome system. For example, lowdensity lipoprotein receptor-related protein 1 (LRP1), part of the low-density
lipoprotein receptor family, mediates endocytosis of LDL cholesterol (Lillis et al.,
2015). Knockdown of LRP1 in mice increases LDL serum levels and increases
cholesterol levels in isolated macrophages. Additionally, LRP1 is linked to
amyloid beta clearance and is shown to be involved in multiple pathways that are
associated with AD reviewed by (Kanekiyo & Bu, 2014). In the context of LSR,
de-acidification of lysosomes promoted amyloidogenesis (X. Chen, Hui, Geiger,
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Haughey, & Geiger, 2013; Hui et al., 2019). An interesting question would be to
determine the surface levels of LRP1 in in vitro and in vivo models of AD.
Moreover, it might be the case that LRP1 surface level expression is reduced
resulting in the extracellular accumulation of senile plaques. Although
unexplored, a better understanding of LSR might reveal novel mechanisms
underlying AD pathogenesis.
Late endosomes and lysosomes can export cholesterol through lysosomal
membrane localized export channels; Niemann Pick C1 and 2 (NPC1/2) (Davies
& Ioannou, 2000; Friedland, Liou, Lobel, & Stock, 2003). Endolysosome
enlargement and reduction in luminal lysosome calcium levels are evident in
Niemann Pick-type C disease, a LSD, where lysosomes are unable to export
cholesterol resulting in an accumulation of cholesterol (Jin, Shie, Maezawa,
Vincent, & Bird, 2004; Liao et al., 2007; Lloyd-Evans et al., 2008). LDL
cholesterol treatment can induce LSR-type responses both in vitro and in vivo;
lysosomes were enlarged in skeletal muscles of rabbits fed a cholesterol-rich diet
(X. Chen, Ghribi, & Geiger, 2008). Further, endolysosomes in primary cortical
neurons treated with apolipoprotein B-containing LDL were enlarged, deacidified, and contained increased levels of cholesterol and amyloid beta (Hui,
Chen, & Geiger, 2012). Mechanistically, inactivating mTOR and increasing
lysosome activity can reduce cholesterol aggregation in NPC cells (W. Wang et
al., 2015).
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Nanomaterials.
Nanomaterials can traffic into cells via endocytosis (Oh & Park, 2014) and affect
the morphology and function of endolysosomes (Jia et al., 2018; Manshian,
Pokhrel, Madler, & Soenen, 2018; Y. Ye et al., 2019). While some nanomaterials
have been found to be harmful others have protective properties. Silica
nanoparticles de-acidified endolysosomes, increased amyloid-beta peptide
secretion, and reduced levels of calcium in endolysosomes (Y. Ye et al., 2019).
They have also been found to inhibit mTOR activity and increase nuclear TFEB
localization (Jia et al., 2018). Silica nanoparticles also increased lysosome
activity and degraded more readily compared to gold nanoparticles (Manshian et
al., 2018). Gold nanoparticles also seem to cause dysfunction of endolysosomes;
they promoted lysosome enlargement and alkalinization, inactivated mTOR, and
inhibited fusion of lysosomes with autophagosomes (Ma et al., 2011).
Conversely, beneficial effects of acidic nanoparticles on endolysosome function
have been observed; carboxyl-modified polystyrene nanoparticles activated the
TFEB-mTOR pathway and inhibited ferroptosis (L. Li et al., 2019). Poly (DLlactide-co-glycolide) (PLGA) acidic nanoparticles (aNP) were found to
accumulate in endolysosomes, re-acidify endolysosomes, and restore lysosome
functionality (Baltazar et al., 2012). In models of Parkinson's disease, PGLA-aNP
re-acidified endolysosomes, decreased lysosome membrane permeabilization,
and protected against PD-related neuronal degeneration (Bourdenx et al., 2016).
Similarly, in presenilin 1 knock out cells, PGLA-aNP attenuated de-acidification,
lysosomal calcium efflux, and autophagy (J. H. Lee et al., 2015).
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Drugs of abuse (morphine and methamphetamine).
Several drugs of abuse including opioids and amphetamines may cause LSR;
they are up-taken into endolysosomes, increase luminal pH, cause vacuolization,
permeabilize membranes, and disrupt iron homeostasis (Cubells, Rayport,
Rajendran, & Sulzer, 1994; Funakoshi-Hirose et al., 2013; Liesse, Lhoest,
Trouet, & Tulkens, 1976; Nash et al., 2019; Patierno et al., 2011; E. Xu, Liu, Liu,
Wang, & Xiong, 2018). Methamphetamine increased lysosome size, inhibited
autophagosome-lysosome fusion (Funakoshi-Hirose et al., 2013; Nara, Aki,
Funakoshi, Unuma, & Uemura, 2012), de-acidified lysosomes, impaired
phagocytosis, inhibited antigen presentation, and inhibited macrophage functions
during immune responses (Talloczy et al., 2008). Similarly, the opioid morphine
damaged lysosomes; morphine alone and in combination with HIV-1 increased
lysosome pH, and inhibited fusion between autophagosomes and lysosomes (ElHage et al., 2015), induced iron efflux from endolysosomes (Nash et al., 2019),
and increased lysosome pH through mu-opioid receptor-mediated mechanisms
(Nash et al., 2019).
Many clinically used drugs share the physicochemical property of being weakly
or strongly basic. As such and similar to what has been demonstrated for opioids
and methamphetamine, these basic drugs accumulate in acidic endolysosomes
where they would become increasingly charged and where they would be
expected to de-acidify endolysosomes. And recent evidence supports that some
of the following drugs may induce lysosome stress and illicit what we would
characterize as LSR. Commonly used basic drugs (listed in alphabetical order)
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include; antipyrine (analgesic), barbiturates (sedative/hypnotics), bupivacaine
(local anesthetic), chlorpromazine and olanzapine (antipsychotics), diazepam
(anxiolytic), pentazocine (opioid agonist/antagonist), phenylbutazone (NSAID),
propranolol (beta blocker), pyrimethamine (anti-parasitic), quinidine
(antiarrhythmic), sildenafil citrate (erective dysfunction), telmisartan (antihypertensive), tolbutamide (sulfonylurea), valproic acid and phenytoin
(anticonvulsants), warfarin (anticoagulant) (Boz, Hu, Yu, & Huang, 2020; Cramb,
1986; Hamaguchi, Haginaka, Tanimoto, & Kuroda, 2014; Jang et al., 2016;
Kozako et al., 2016; Pourahmad et al., 2012; Staneva-Stoicheva, Krustev, &
Kitova, 1977).
Thus, the possibility exists that any drug, pathogen, or material that enters into
the greater endolysosomal system may induce, to varying degrees, lysosome
stress and LSR (Figure 2). Of course, the definition of LSR will likely change as
new knowledge is added and specific therapeutics are developed, and it is
unclear the extent to which LSR might be protective or destructive. Likely, LSR
occurs in combination with other intracellular stress responses including those
mediated through ER and mitochondria.
Inter-Organellar Signaling
In this era of modern cell biology, there is ever-growing appreciation of the
complexities of inter-organellar signaling in health and disease (Afghah et al.,
2020; Gottschling & Nystrom, 2017; Khan, Haughey, et al., 2019). Organelles are
highly mobile in cells and dynamically form contacts between organelles; as such
extensive communications between organelles exists (Deus et al., 2020; Soto143

Heredero, Baixauli, & Mittelbrunn, 2017). Inter-organellar signaling helps
maintain cellular functions (Deus et al., 2020; Gottschling & Nystrom, 2017).
Cell stress can cause disrupted crosstalk between organelles (Deus et al., 2020;
Guerra et al., 2019; Soto-Heredero et al., 2017; Torres et al., 2017). For
example, mitochondria, ER, and endolysosome dysfunction are implicated in
multiple diseases and disorders (Annunziata, Sano, & d'Azzo, 2018; Audano et
al., 2018; Demers-Lamarche et al., 2016; Plotegher & Duchen, 2017; SotoHeredero et al., 2017; Torres et al., 2017). Cellular stress signals converge on
one common adaptive pathway, termed the integrated stress response (ISR)
(Pakos-Zebrucka et al., 2016). The integration point of stress stimuli occurs at
the phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2) and
subsequent synthesis of activating transcription factor 4 (ATF4), which is a
transcription factor that upregulates genes that promote cellular survival and
recovery (Pakos-Zebrucka et al., 2016). ISR can stimulate autophagy pathways
and is suggested to promote regulation of cellular fate (Humeau et al., 2020;
Kroemer, Marino, & Levine, 2010). The type and duration of a stressor plays an
important factor in the outcomes of the ISR. Stress signals from both ER and
mitochondrial participate in ISR, although, it remains unclear the degree to which
LSR contributes to ISR.
LSR Observed in ER- and Mitochondrial Stress Responses
Endolysosomes dynamically interact physically and chemically with the nucleus,
ER and mitochondria (Deus et al., 2020; C. A. Lee & Blackstone, 2020;
Settembre et al., 2013) and such inter-organellar signaling might affect organellar
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stress responses. Indeed, ER and mitochondrial stress can induce LSR
(Table 5). ER stress de-acidifies lysosomes, increases lysosome size, induces
lysosome membrane permeabilization, and leads to lysosome repositioning (D.
Bae, Moore, Mella, Hayashi, & Hollien, 2019; Dauer et al., 2017; Elfrink, Zwart,
Baas, & Scheper, 2013; A. Kim & Cunningham, 2015; Nakashima et al., 2019).
Moreover, it inhibits autophagic flux (Nakashima et al., 2019). Pharmacological
induction of ER stress with tunicamycin causes nuclear translocation of the
transcription factors TFEB and TFE3 (Martina et al., 2016). Further, the lysosome
resident protein mTOR contributes to ER stress, and cell life and death by
regulating expression levels of ER stress response genes (Appenzeller-Herzog &
Hall, 2012; G. Dong et al., 2015). However, there is evidence of mTORindependent nuclear translocation of TFEB/3 (Martina et al., 2016).
Similar to ER, LSR is observed in mitochondrial stress such as lysosome
membrane permeabilization, de-acidification, changes in morphology, LDL
cholesterol accumulation, and misfolded protein aggregation (Baixauli et al.,
2015; Butler & Bahr, 2006; Demers-Lamarche et al., 2016; Hwang, Lee, Kim,
Cho, & Koh, 2008; Schieber & Chandel, 2014; X. Zhang et al., 2016). Deacidification of endolysosomes promotes efflux of redox active iron into the
cytosol which can then generate ROS through the Fenton reaction in the cytosol
and within mitochondria (Uchiyama et al., 2008; Yambire et al., 2019). H O 2

2

induced oxidative stress suppressed TFEB nuclear translocation and promoted
apoptosis (Q. Su et al., 2018) and TFEB-overexpression was protective; it
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Table 5. Comparison of lysosome, mitochondria and ER stress responses. This table highlights
the absence or presence of evidence for the observation of LSR in mitochondrial- and ER-stress
responses. (+) indicate evidence for LSR, while (-) indicate a lack of evidence for LSR, while (-)
indicate a lack of evidence for LSR.
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reduced glucose-mediated oxidative stress by increasing the expression of
antioxidant enzymes and mitochondrial biogenesis genes (Kang, Li, Zhang, Chi,
& Liu, 2019), and increased autophagy (F. Li et al., 2016).
Broader Implications
In comparison to ER and mitochondrial stress responses, relatively little is known
about LSR. PubMed and Google Scholar searches for the keywords "ER stress",
"unfolded protein response", “mitochondrial stress”, “mitochondrial redox
catastrophe”, and “mitochondrial bioenergetic crisis” generate citations to
thousands of manuscripts. Conversely, a search for the keywords "lysosomal
stress" or "lysosome stress response" yields less than one dozen manuscript
citations; only a few attempted to define lysosome stress. Similar to ER and
mitochondria, when presented with excess cargo, lysosomes can undergo stress
responses implicated in multiple pathologies (Davidson & Vander Heiden, 2017;
Lie & Nixon, 2019; Reuser & Drost, 2006). Thus, establishing a framework for
defining LSR is of physiological and pathological importance. Central to the
criteria described above for LSR are lysosome de-acidification and lysosome
membrane permeabilization. Any drug, protein, virus or insult that affects the
endocytic or autophagic pathways may cause lysosome stress and trigger LSR.
Conclusions
Lysosomes are integral to the dynamic endolysosome system and are important
for maintaining cellular homeostasis through intracellular degradation of cargo,
cytosolic nutrient sensing, and cation homeostasis. Under stressful conditions all
organelles including lysosomes, ER and mitochondria exhibit stress responses
147

as they attempt to restore organellar function or promote cell death pathways
when stress responses are too great. Few have provided characterizations of
LSR and here a framework is presented upon which we can build on the
physiological roles and pathological implications for LSR. Through a better
understanding of LSR, new and potentially impactful therapeutic interventions
might be discovered. In the meantime, LSR might find its place in the vernacular
of modern cell biology and might lead to a wave of investigations focused on
inter-organellar signaling (Figure 27).
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Figure 27.

Organellar stress responses. Resulting from acute and chronic
stimuli and stressors, lysosomes can exhibit lysosome stress
responses (LSR). LSR as characterized in the text and in
Figure 3 is characterized by perinuclear to peripheral
repositioning of lysosomes, increases in lysosome size,
reduction in intralysosomal proton concentrations and decreases
in cytosolic and extracellular pH, intraluminal accumulation of
LDL cholesterol, increased misfolded protein aggregation,
lysosomal membrane permeabilization, and efflux of calcium and
iron from lysosomes. Endoplasmic reticulum (ER) and
mitochondria exhibit their own stress responses, and these might
be triggered by LSR. Mitochondria in response to increases in
cytosolic iron and calcium act as cation sinks; when excessive
results include increases in reactive oxygen species (ROS)
leading to redox catastrophe and decreases in adenosine
triphosphate (ATP) promoting bioenergetic crisis. A vicious cycle
can result from LSR including (1) increases in ROS can cause
further lysosome stress, (2) increases in cytosolic calcium can
trigger calcium-induced calcium release from ER, and (3)
increases in lipid accumulation and protein aggregation in ER
can lead to ER stress. Therefore, LSR might be an early and
upstream event that participates in inter-organellar stress
responses.
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CHAPTER 5
GENERAL DISCUSSION
Conclusions
Iron is both essential and detrimental to cells. It is involved in many life sustaining
processes; when levels of free iron increase it leads to the production of radical
species that damage DNA, proteins, and lipids (Wallace, 2016). Iron is a redox
active metal and is mainly found in either its ferrous (Fe2+) or ferric (Fe3+) form.
Ferric iron is redox inactive and is the form that is transported throughout the
body. Systemic iron transport is aided by the iron transport glycoprotein,
transferrin (TF) (Ponka & Lok, 1999). TF has a high binding affinity for two Fe3+
ions which protects the body from the formation of insoluble ferric hydroxides and
redox active ferrous form of iron (Muckenthaler et al., 2017; D. R. Richardson et
al., 2010). Cells contain transmembrane glycoprotein transferrin receptors (TFR)
which allow them to take up iron-bound TF via receptor-mediated endocytosis.
This leads to an accumulation of Fe3+ within endolysosomes and that
accumulated Fe3+ can be reduced to Fe2+ by ferrireductase protein STEAP3
(Muckenthaler et al., 2017; Ponka & Lok, 1999; Wallace, 2016). After being
reduced, Fe2+ is released through endolysosome-resident iron permeable
channels such as DMT-1 and TRPML1 (Abouhamed et al., 2006; X. P. Dong et
al., 2008). It is evident that endolysosomes are critical for cellular iron
homeostasis. This is where our study begins.
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The Geiger/Chen laboratory is interested in understanding the role that
endolysosome de-acidification plays in neurogenerative disease pathologies.
Over 50% of PLWH develop neurocognitive impairments termed HIV-1
associated neurocognitive disorder (HAND) (Antinori et al., 2007; Clifford &
Ances, 2013; McArthur et al., 2010). There is currently no cure for HAND and the
underlying mechanisms for its pathogenesis are still under investigation.
However, elevated serum iron levels and soluble factors such as HIV-1 protein
gp120 have been hypothesized to contribute to HAND pathogenesis (Chang et
al., 2015; Kovalevich & Langford, 2012). HIV-1 gp120 induces astrocyte
dysfunction, increases ROS production and affects the function and morphology
of organelles including endolysosomes (M. Bae et al., 2014; Datta et al., 2019;
Lopez et al., 2017; Raber et al., 1996). Thus, in these studies we investigated
mechanisms by which HIV-1 gp120 affects cellular iron homeostasis in U87MG
cells, an astrocytoma cell line; these cells have been used by others to
investigate the cellular effects of HIV-1 gp120 (Lopez et al., 2017; ValentínGuillama et al., 2018).
In Chapter 2, we determined an intracellular mechanism by which HIV-1 gp120
affects ROS production through endolysosome-based iron release. We observed
that HIV-1 gp120 induced, within a 30 min duration, endolysosomal deacidification which led to a reduction in luminal levels of endolysosome iron and
increases in cytosolic and mitochondrial iron levels. Subsequently, an increase of
ROS was observed in the cytosol and mitochondria, and these increases were
blocked by chelating endolysosome iron with DFO. Interestingly, this
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phenomenon occurred in the absence of significant cell death even when we
extended our treatments to 24 h. Results from other groups confirmed our
findings and provide evidence that HIV-1 gp120 treatment increases cell
proliferation in U87MG cells through glycolysis and promoting the unfolded
protein response (Lopez et al., 2017; Valentín-Guillama et al., 2018).
The study conducted in Chapter 3 is an extension of our first study. HIV-1 gp120
increased cytosolic and mitochondrial ROS levels within 30 min of treatment but
did not induce cell death at 24 h. This led us to question whether HIV-1 gp120
had significant effects on iron related proteins in U87MG cells. We first
determined the responsiveness of our U87MG cells to changes in intracellular
iron levels. DFO and FAC were used to decrease and increase the intracellular
liable pool of iron, respectively (Hoepken et al., 2004). We treated our cells at
varying time points and concentrations of each compound. Our results
demonstrated to us that 24 h treatment with either 100 µM DFO or 100 µM FAC
induced a significant increase TFR1 or FTH, respectively. Conversely, 100 µM
FAC reduced TFR1, while 100 µM DFO reduced FTH. Thus, moving forward we
decided to use a 24 h treatment time point for our studies. We hypothesized that
24 h HIV-1 gp120 would lead to decreases in TFR1 and IRP2 protein, and
increases in FTH and FPN protein. To our surprise we did not observe any effect
of gp120 on surface or total protein levels of TFR1 and there was no significant
changes in IRP2 or FTH protein levels. But, we did observe a significant increase
in surface FPN. One explanation for this finding is that U87MG cells might
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increase surface levels of FPN in order to release excess iron from the cells and
maintain homeostasis.
In Chapter 4, we detailed our definition of lysosomal stress response (LSR)
which is a homeostatic regulatory response initiated by lysosomes when they
encounter a stressor such as HIV-1 gp120. We have categorized LSR as
(1) increased intralysosomal pH, (2) increased lysosome size, (3) membrane
permeabilization, (4) cationic efflux, (5) repositioning intracellularly, (6) misfolded
protein aggregation, (7) LDL cholesterol accumulation, (8) redox catastrophe,
and (9) bioenergetic crisis. The response varies based on the LSR inducer and
duration of the stress. In the case of HIV-1 gp120 it is apparent to us that during
short term treatments (30 min), HIV-1 gp120 is able to de-acidify endolysosomes,
increase endolysosome size and decrease the number of endolysosomes while
also inducing the efflux of iron from endolysosomes. Although we didn’t test it,
this response may be upstream of the UPR response and induce acute ERstress (Lopez et al., 2017). Thus, inter-organellar signaling maybe a contributor
to HAND pathogenesis.
There is far more work to be done and many more questions to asked. Such as,
what are the effects of 24 h gp120 treatment on intracellular iron levels; how do
endolysosome iron stores contribute to 24 h gp120-induced increases in surface
FPN; does inhibition of gp120 internalization into U87MG cells block its deacidifying effects on endolysosome and the downstream consequences; how
does acidifying endolysosomes affect gp120 effect on endolysosome, cytosol
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and mitochondrial iron communication; how does HIV-gp120 affect intracellular
iron signaling between endolysosomes and mitochondria in primary astrocytes?
Limitations
We appreciate that the experiments conducted and presented in this dissertation
have several limitations. Hence, we will briefly discuss some of them in this
section. In Chapter 2, we assumed that HIV-1 gp120 was being internalized into
the endolysosomes. We did not check whether our cells expressed either
receptor, CXCR4 or CCR5, for gp120. Furthermore, we did not conduct any
studies with CXCR4 or CCR5 antagonists to determine whether gp120-induced
endolysosome de-acidification was a direct or indirect affect. Moreover, our study
used only a pharmacological approach to determine the mechanism by which
HIV-1 gp120 induced iron release from endolysosomes and how that iron was
taken up by mitochondria. To confirm this mechanism, the use of molecular
techniques such as knockdown of FPN and TFR1 would be necessary. Another
limitation is that at the time that these experiments were carried out we did not
have the ability to simultaneously measure iron levels in endolysosomes, cytosol,
and mitochondria in live cells.
In Chapter 3, we did not measure levels of endolysosome, cytosol or
mitochondrial iron and ROS levels during our treatment 24 h time period.
Therefore, we do not know if 24 h HIV-1 gp120 treatment increases cytosolic iron
levels. Furthermore, our work did not involve any qPCR analyses to determine
changes in mRNA transcripts due to our HIV-1 gp120 treatment. It is possible
that HIV-1 gp120 increases the mRNA transcripts of TFR1 and FTH and the time
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period we decided on was too short to observe changes in protein levels. We
also did not run time course experiments to rule out that 24 h HIV-1 gp120 does
not affect the iron related proteins tested in this study. Nonetheless, without
these experiments it remains unclear as to how HIV-1 gp120 is affecting these
proteins.
Most importantly, our cell model used for this study is limiting. Although U87MG
cells have been used to investigate the effects of HIV-1 gp120, these cells are
cancer cells, which are reported to have higher levels of ROS compared to noncancer cells (Liou & Storz, 2010; Schieber & Chandel, 2014); they also proliferate
in the presence of ROS due to an elevation of antioxidants to maintain cell
survival (Liou & Storz, 2010). Therefore, these cells have modified signaling
pathways to promote cell survival and replication and avoid cell death.
Future Directions
Despite these limitations, we think that this work provides a proof of concept for
HIV-1 gp120 induced endolysosome iron release which can promote cytosolic
and mitochondrial ROS production. Furthermore, our findings demonstrate that
HIV-1 gp120 promotes an increase in surface FPN levels in U87MG cells. One
way this work can be extended is repeating these studies in human primary
astrocytes. We would be able to determine if 1) this endolysosome-mitochondrial
iron/ROS mechanism is occurring, 2) does this mechanism induce cell death,
and 3) can that cell death be prevented by blocking endolysosome iron release?
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Our investigation of changes in iron regulatory proteins due to the presence of
HIV-1 gp120 can also be extended using a rodent model; HIV-1 gp120
transgenic mice (Toggas et al., 1994). HIV-1 gp120 transgenic mice express
HIV-1 gp120 in astrocytes and is under the control of the glial fibrillary acidic
protein promoter (GFAP-gp120tg) (Toggas et al., 1994). The GFAP-gp120tg
mice demonstrates reduced autophagy, protein aggregates, hippocampal
damage, loss of dendrites and synapses and astrogliosis all of which are
involved in HAND neuropathogenesis (J. Fields et al., 2013; Thaney et al., 2018;
Toggas et al., 1996). We could set up a study comparing wild-type and GFAPgp120tg mice in the absence or presence of DFO. The mice would be separated
into male and female groups within the WT and gp120 groups. Furthermore, the
animals would be raised to maturity (around 3-6 months) and then PBS or DFO
(100 mg/kg, twice daily) would be given intraperitoneally for 7 days (Y. Li, K. Pan,
et al., 2016). Then, a portion of WT and gp120 mice would be euthanized and
brains would be homogenized and the protein levels determined for FPN, IRP2,
FTH, and TFR1. The brains of another subset of WT and gp120 would be sliced
and stained using, immunohistochemistry to measure levels of the above listed
iron-related proteins. The remaining mice would undergo neurocognitive and
motor coordination evaluations. There is still much work to be done, but these
studies provide a foundation for evidence of intra-organellar iron signaling in the
context of HAND.
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